<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006449" GROUP_ID="NEONATAL" ID="744506100107534168" MERGED_FROM="" MODIFIED="2009-02-18 18:30:23 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;sent to Shah Feb 11-07&lt;/p&gt;&lt;p&gt;approved by Shah Feb 12-07&lt;/p&gt;&lt;p&gt;CL 2/07 protocol&lt;/p&gt;&lt;p&gt;sent to P. Shah Sept 13-07&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-02-18 12:05:29 -0500" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-02-18 18:30:23 +0100" MODIFIED_BY="Diane Haughton">
<TITLE>Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants</TITLE>
<CONTACT MODIFIED="2009-02-18 18:30:23 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="12333" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Prakeshkumar</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Shah</LAST_NAME><POSITION>Staff Neonatologist, Mount Sinai Hospital</POSITION><EMAIL_1>pshah@mtsinai.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics and Department of Health Policy, Management and Evaluation, Rm 775A</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><ADDRESS_1>600 University Avenue</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1XB</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416 586 4761</PHONE_1><PHONE_2>+1 416 334 6661</PHONE_2><FAX_1>+1 416 586 8745</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-02-18 18:30:23 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="12333" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Prakeshkumar</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Shah</LAST_NAME><POSITION>Staff Neonatologist, Mount Sinai Hospital</POSITION><EMAIL_1>pshah@mtsinai.on.ca</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatrics and Department of Health Policy, Management and Evaluation, Rm 775A</DEPARTMENT><ORGANISATION>University of Toronto</ORGANISATION><ADDRESS_1>600 University Avenue</ADDRESS_1><CITY>Toronto</CITY><ZIP>M5G 1XB</ZIP><REGION>Ontario</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 416 586 4761</PHONE_1><PHONE_2>+1 416 334 6661</PHONE_2><FAX_1>+1 416 586 8745</FAX_1></ADDRESS></PERSON><PERSON ID="F7470C2B82E26AA2005EBC6EBAF6B813" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Kaufman</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>DAK4R@hscmail.mcc.virginia.edu</EMAIL_1><ADDRESS><DEPARTMENT>Pediatrics</DEPARTMENT><ORGANISATION>University of Virginia School of Medicine</ORGANISATION><CITY>Charlottesville</CITY><ZIP>22908</ZIP><REGION>Virginia</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>1 434 924 9114</PHONE_1><FAX_1>1 434 924 2816</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-02-17 16:11:19 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="9" MONTH="2" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="9" MONTH="2" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="9" MONTH="2" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2009-02-10 10:01:16 -0500" MODIFIED_BY="[Empty name]"/>
<HISTORY MODIFIED="2009-02-10 10:01:11 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-02-10 10:01:11 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Paediatrics, Mount Sinai Hospital, University of Toronto</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Department of Pediatrics, University of Virginia Medical School</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-02-18 12:05:29 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-02-18 12:02:58 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-02-08 12:53:59 -0500" MODIFIED_BY="[Empty name]">Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants</TITLE>
<SUMMARY_BODY MODIFIED="2009-02-18 12:02:58 -0500" MODIFIED_BY="[Empty name]">
<P>Babies born at earlier gestation and who are born with low birth weight are at significant risk of sepsis. This is in part due to the immaturity of the immune defence system, including low levels of immunoglobulins. Researchers attempted to boost the immune system by artificially providing antibodies specific to the most common bacteria causing such infections. Three studies reviewed here (two of which are pilot studies) revealed neither benefit nor risk associated with the preventative use of specific antibodies to common bacterial infections.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-02-18 12:03:40 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-10-21 15:12:02 -0400" MODIFIED_BY="[Empty name]">
<P>Nosocomial infection is a major problem affecting the immediate health and long-term outcome of preterm and very low birth weight neonates. More than half of these infections are caused by staphylococci. Various type specific antibodies targeted at different antigenic markers of Staphylococcus have been developed and have shown promise in animal studies.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-01-30 13:08:50 -0500" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and safety of antistaphylococcal immunoglobulins in the prevention of Staphylococcal infection in very low birth weight infants.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-02-17 16:12:04 -0500" MODIFIED_BY="[Empty name]">
<P>Medline, Embase, CINAHL, Cochrane Central Register of Controlled Trials (The Cochrane Library) were searched from their inception until February 2009. In addition, abstracts of major pediatric meetings of last seven years were searched.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-02-18 12:03:40 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized and quasi-randomized studies of antistaphylococcal immunoglobulins for the prevention of staphylococcal infections in preterm or very low birth weight neonates were reviewed by both authors for their eligibility for inclusion. Studies of any dose and/or route were included. Quality of studies was evaluated using criteria of masking of randomization, masking of intervention, completeness of follow-up and masking of outcome assessment by both review authors.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-01-30 13:18:03 -0500" MODIFIED_BY="[Empty name]">
<P>Data from the primary author were obtained where published data provided inadequate information for the review or where relevant data could not be abstracted. Data were abstracted independently by both review authors. Statistical methods included calculation of relative risk (RR), risk difference (RD), number needed to treat (NNT) and weighted mean difference (WMD) when appropriate. Ninety five percent confidence intervals (CI) was used for these estimates of treatment effects. A fixed effect model was used for meta-analyses. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-02-18 10:43:03 -0500" MODIFIED_BY="[Empty name]">
<P>Three eligible studies were included (two studies of INH A-21 and one study of Altastaph involving a total of 2,701 neonates). Three reports of Pagibaximab were published as abstracts and will be considered for inclusion when further information is obtained. There were no significant differences noted in the risk of Staphylococcal infection between INH A-21 vs. placebo (typical RR 1.07, 95% CI 0.94, 1.22) or Altastaph vs. placebo (RR 0.86, 95% CI 0.32, 2.28); the risk of other bacterial infection between INH A-21 vs. placebo (typical RR 0.87, 95% CI 0.72, 1.06) or Altastaph vs. placebo (RR 0.93, 95% CI 0.53, 1.64); or the risk of any infection between INH A-21 vs. placebo (RR 1.00, 95% CI 0.91, 1.09) or Altastaph vs. placebo (RR 0.93, 95% CI 0.54, 1.62). There was no significant difference in the incidence of relevant secondary outcomes (chronic lung disease at 28 days, patent ductus arteriosus, necrotizing enterocolitis, intraventricular hemorrhage, retinopathy of prematurity or duration of antibiotic and vancomycin use).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-10-21 15:13:27 -0400" MODIFIED_BY="[Empty name]">
<P>Antistaphylococcal immunoglobulins (INH A-21 and Altastaph) are not recommended for prevention of staphylococcal infections in preterm or VLBW neonates. Further research to investigate the efficacy of other products such as Pagibaximab is needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-02-18 12:05:29 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-02-18 12:03:58 -0500" MODIFIED_BY="[Empty name]">
<P>Nosocomial infections are reported in approximately 20 - 25% of very low birth weight neonates (<LINK REF="REF-Stoll-2002" TYPE="REFERENCE">Stoll 2002</LINK>). The incidence is higher at lower gestational age and lower birth weights, reaching 50% in infants with birth weight &lt; 750 g. Approximately half of these infections are caused by Staphylococcus Epidermidis and another 5 - 8% of infections are caused by Staphylococcus Aureus (<LINK REF="REF-Stoll-2002" TYPE="REFERENCE">Stoll 2002</LINK>). Reduced amount of fetal antibodies, structural limitations reducing affinity of these antibodies to antigens, and functional deficiency of B and T lymphocytes have been proposed as mechanisms for compromised host defenses in the neonate (<LINK REF="REF-Splawski-1991" TYPE="REFERENCE">Splawski 1991</LINK>; <LINK REF="REF-Schroeder-1995" TYPE="REFERENCE">Schroeder 1995</LINK>). Presence of central venous catheters, multiple intravenous attempts, poor skin integrity and the use of total parenteral nutrition including lipids are considered significant predisposing factors (<LINK REF="REF-Stoll-2002" TYPE="REFERENCE">Stoll 2002</LINK>). The systemic inflammatory response secondary to infection may increase the risk of death and severe neurological handicap (<LINK REF="REF-Gray-1995" TYPE="REFERENCE">Gray 1995</LINK>; <LINK REF="REF-Adams_x002d_Chapman-2006" TYPE="REFERENCE">Adams-Chapman 2006</LINK>; <LINK REF="REF-Stoll-2004" TYPE="REFERENCE">Stoll 2004</LINK>). Sepsis is associated with increased length of stay, severe intraventricular hemorrhage, periventricular leukomalacia, neurodevelopmental impairment, chronic lung disease, increased number of days on ventilator support and increased cost to health care systems (<LINK REF="REF-Fanaroff-1998" TYPE="REFERENCE">Fanaroff 1998</LINK>; <LINK REF="REF-Graham-2004" TYPE="REFERENCE">Graham 2004</LINK>; <LINK REF="REF-Stoll-2004" TYPE="REFERENCE">Stoll 2004</LINK>; <LINK REF="REF-Stoll-2002" TYPE="REFERENCE">Stoll 2002</LINK>).</P>
<P>Practices that have shown to reduce nosocomial infections include appropriate hand hygiene, nutrition, skin care, vascular access care and improving the "culture" of intensive care (<LINK REF="REF-Horbar-2001" TYPE="REFERENCE">Horbar 2001</LINK>). Other strategies to reduce infection including administration of prophylactic antibiotics, antifungal agents, colony stimulating factors, immunoglobulin and topical emollient ointments have met with variable success (<LINK REF="REF-Kaufman-2004" TYPE="REFERENCE">Kaufman 2004</LINK>; <LINK REF="REF-Banerjea-2002" TYPE="REFERENCE">Banerjea 2002</LINK>; <LINK REF="REF-Conner-2004" TYPE="REFERENCE">Conner 2004</LINK>). Multiple clinical trials have evaluated the role of pooled generic human immunoglobulins in the prevention and treatment of nosocomial infections. A systematic review of generic immunoglobulin administration to prevent infections demonstrated only a 3% reduction in the incidence of infections without any significant change in mortality (<LINK REF="REF-Ohlsson-2004" TYPE="REFERENCE">Ohlsson 2004</LINK>; <LINK REF="REF-Ohlsson-2004a" TYPE="REFERENCE">Ohlsson 2004a</LINK>). This may be due to the low titre of type specific antibodies (<LINK REF="REF-Schroeder-1995" TYPE="REFERENCE">Schroeder 1995</LINK>; <LINK REF="REF-Splawski-1991" TYPE="REFERENCE">Splawski 1991</LINK>; <LINK REF="REF-Kaufman-2006" TYPE="REFERENCE">Kaufman 2006</LINK>) and variable activity of these preparations against the common infective agent Staphylococcus Epidermidis (<LINK REF="REF-Weisman-2004" TYPE="REFERENCE">Weisman 2004</LINK>). This concern is supported by "batch to batch" variation in the amount of antibodies against Staphylococcus Epidermidis (<LINK REF="REF-Weisman-1994" TYPE="REFERENCE">Weisman 1994</LINK>).</P>
<P>Recently, various type specific antibodies targeted at different antigenic markers of Staphylococcus have been developed and have shown promise in animal studies and phase one studies (<LINK REF="REF-Kaufman-2006" TYPE="REFERENCE">Kaufman 2006</LINK>; <LINK REF="REF-Patti-2005" TYPE="REFERENCE">Patti 2005</LINK>). These include Altastaph (antibody against capsular polysaccharide antigen type 5 and 8), Staphvax (Staphylococcus polysaccharide conjugate vaccine), BSYX-A110 (anti-lipoteichoic acid monoclonal antibody), Veronate or INH-A21 (antibody against "microbial surface components recognizing adhesive matrix molecules" [MSCRAMMS]), and Aurexis (monoclonal antibody to clumping factorA) (<LINK REF="REF-Patti-2005" TYPE="REFERENCE">Patti 2005</LINK>; <LINK REF="REF-Kaufman-2006" TYPE="REFERENCE">Kaufman 2006</LINK>). In a neonatal rat model, Veronate was shown to increase phagocytic activity and had both prophylactic and therapeutic effects (<LINK REF="REF-Vernachio-2006" TYPE="REFERENCE">Vernachio 2006</LINK>). Veronate was well tolerated and had a safety profile similar to generic immunoglobulin (<LINK REF="REF-Capparelli-2005" TYPE="REFERENCE">Capparelli 2005</LINK>). Phase 1 studies of Veronate demonstrated increased antibody titre in human recipients (<LINK REF="REF-Capparelli-2005" TYPE="REFERENCE">Capparelli 2005</LINK>). However, these preparations are also likely to have side effects similar to those of generic immunoglobulin, including allergic reactions, potential for transmission of blood-borne infections, and infusion related side effects due to the their large volume (<LINK REF="REF-Kaufman-2006" TYPE="REFERENCE">Kaufman 2006</LINK>; <LINK REF="REF-Singh_x002d_Grewal-2006" TYPE="REFERENCE">Singh-Grewal 2006</LINK>). These side effects could potentially contribute to increased incidence of intracranial hemorrhage, patent ductus arteriosus, necrotizing enterocolitis and bronchopulmonary dysplasia. Additionally, in preterm and very low birth weight infants, these specific products may not be effective due to other aspects of poor innate immunologic response, such as immature white blood cells and deficient complement system (<LINK REF="REF-Kaufman-2006" TYPE="REFERENCE">Kaufman 2006</LINK>).</P>
<P>This review evaluates the effects of administration of organism specific antistaphylococcal immunoglobulin on preventing late-onset sepsis in very low birth weight infants or infants &#8804; 32 weeks gestation.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-02-18 12:04:03 -0500" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and safety of antistaphylococcal immunoglobulins in the prevention of Staphylococcal infection in preterm and very low birth weight infants.</P>
<P>Comparison will include:</P>
<OL>
<LI>Any antistaphylococcal immunoglobulin compared to placebo or no treatment</LI>
<LI>Different types of antistaphylococcal immunoglobulins compared to placebo or no treatment</LI>
<LI>One type of antistaphylococcal immunoglobulin compared to another type of antistaphylococcal immunoglobulin.</LI>
</OL>
<P>Within each category subgroup analyses are planned according to birth weight (a) among extremely low birth weight infants (&lt; 1000 g) and (b) different types of immunoglobulins.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-02-18 12:04:45 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-02-18 10:55:07 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-10-21 15:16:06 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized or quasi-randomized controlled trials of any type of antistaphylococcal immunoglobulin vs. placebo or no intervention for prevention of Staphylococcal infection in very low birth weight infants were included. Cluster trials were not included. Studies reporting on any primary or secondary outcomes were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-11-07 10:49:45 -0500" MODIFIED_BY="[Empty name]">
<P>Very low birth weight (&lt; 1500 g) infants who received placebo, no intervention or antistaphylococcal immunoglobulins before 28 days of age. Only studies in which subjects received antistaphylococcal immunoglobulin at the time when they were clinically deemed free of infection were included. If the study enrolled patients based on gestational age alone, we included only patients <U>&lt;</U> 32 weeks gestational age.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-05-19 08:28:02 -0400" MODIFIED_BY="[Empty name]">
<P>Antistaphylococcal immunoglobulins are defined as immunoglobulins with enriched activity against one of the antigenic component of the organism Staphylococcus. Studies of antistaphylococcal immunoglobulin (of any type) used for the prevention of infection were included. Any route of administration of antistaphylococcal immunoglobulin (intravenous, intramuscular, subcutaneous or oral) was considered. Studies of any duration of administration were considered. Eligible control interventions included placebo, no treatment or another type of antistaphylococcal immunoglobulin. Any study in which participants received antistaphylococcal immunoglobulins for therapeutic purpose was not included.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-02-18 10:55:07 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Primary outcomes:</HEADING>
<P>1. Incidence of Staphylococcal infections after intervention (clinical signs of infection and isolation of Staphylococci from either blood, CSF, urine or other sterile body sites)</P>
<P>2. Incidence of other bacterial infection after intervention (clinical signs of infection and isolation of other bacteria from either blood, CSF, urine or other sterile body sites)</P>
<P>3. Incidence of any infection after intervention (clinical signs of infection and isolation of bacteria/fungi from either blood, CSF, urine or other sterile body sites)</P>
<P>4. Mortality prior to discharge from NICU<BR/>a. Infection related mortality<BR/>b. All cause mortality<BR/>
</P>
<P>All primary outcomes will be measured until discharge from NICU.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Secondary outcomes:</HEADING>
<P>1. Chronic lung disease (defined as oxygen requirement at 36 weeks postmenstrual age [<LINK REF="REF-Shennan-1988" TYPE="REFERENCE">Shennan 1988</LINK>])<BR/>2. Patent ductus arteriosus (PDA) (clinically diagnosed with or without echocardiogram)<BR/>a. PDA treated medically<BR/>b. PDA treated surgically<BR/>3. Necrotizing enterocolitis (NEC) according to <LINK REF="REF-Bell-1978" TYPE="REFERENCE">Bell 1978</LINK> classification<BR/>a. Stage 1 NEC<BR/>b. Stage 2 NEC<BR/>c. Stage 3 NEC<BR/>4. Intraventricular hemorrhage (according to <LINK REF="REF-Papile-1978" TYPE="REFERENCE">Papile 1978</LINK> classification)<BR/>a. Any grade of intraventricular hemorrhage<BR/>b. Grade 3 or grade 4 intraventricular hemorrhage<BR/>5. Periventricular leukomalacia (PVL)<BR/>6. Retinopathy of prematurity (ROP)<BR/>a. Any stage of retinopathy of prematurity<BR/>b. Stage 3 or 4 retinopathy of prematurity<BR/>7. Length of hospitalization (days)<BR/>8. Neurodevelopmental disability at 18 - 24 months (including cerebral palsy, cognitive impairment, deafness and blindness)<BR/>9. Change in the titre of antistaphylococcal antibody levels (as reported by authors)<BR/>10. Incidences of allergic reaction (skin rash, anaphylaxis)<BR/>11. Incidence of transmission of blood borne disease (cytomegalovirus infection, hepatitis B infection, HIV infection)<BR/>12. Duration of any antibiotic use prior to discharge (days)<BR/>13. Duration of Vancomycin use prior to discharge (days)<BR/>14. Clinically important adverse effects reported by authors (pulmonary edema, hypertension, hypoglycemia)<BR/>15. Any clinically important outcome or adverse effects reported by authors (not pre-specified)</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-02-18 12:04:45 -0500" MODIFIED_BY="[Empty name]">
<P>As per Cochrane Neonatal Review Group search strategy:<BR/>
<BR/>MEDLINE was searched (1966 to February 2009) using the following terms which will be combined by "AND".</P>
<P>Population: Infant-Newborn (MeSH) OR Infant-premature (MeSH) OR Infant, Low Birth Weight (MeSH) OR Infant, Very Low Birth Weight (MeSH) OR Infant, Small for Gestational Age (MeSH) OR Infant, Premature, Disease (MeSH) OR Infant, Newborn, Diseases (MeSH) OR newborn (text word) OR infant (text word) OR neonate (text word)<BR/>Intervention: Immunoglobulins, intravenous (MeSH); Intravenous immunoglobulins (MeSH); Intravenous immune globulin (MeSH); Immune globulin, intravenous (MeSH) Immunologic factors (MeSH); Immunological factors (MeSH); Factors, immunologic (MeSH); Factors, immunological (MeSH)<BR/>Comparison: Clinical trials (MeSH) OR Controlled Clinical Trials (MeSH) OR Randomized Controlled Trials (MeSH) OR Random Allocation (MeSH) OR Multicenter studies (MeSH) OR Control groups (MeSH) OR Evaluation studies (MeSH)</P>
<P>Other databases that were searched include: EMBASE (1980 to February 2009); CINAHL (1982 to February 2009); the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 4, 2008, The Cochrane Library) with appropriate terms. We searched the reference lists of identified articles. The reference lists of identified trials, abstracts from the annual meetings of the Society for Pediatric Research, American Pediatric Society and Pediatric Academic Societies published in Pediatric Research (2001 - 2007) were searched. No language restrictions were applied. Authors were contacted in the event of clarification of the data, obtaining relevant data and obtaining data on the outcomes not reported in the manuscript.</P>
<P>The following types of articles were excluded: letters, editorials/commentaries, reviews, lectures.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-21 15:28:44 -0400" MODIFIED_BY="[Empty name]">
<P>All published articles identified as potentially relevant by the literature search were assessed for inclusion in the review by both review authors. In order to be included the trial had to meet the following criteria: 1) the study population had to be very low birth weight neonates; 2) the intervention had to be one of the specific immunoglobulin preparations against Staphylococcal infections; 3) the study had to be a randomized or quasi randomized controlled trial and 4) one or more primary or secondary outcome measures have been reported.</P>
<P>Quality of included trials were evaluated independently by both review authors using the following criteria:</P>
<OL>
<LI>Masking of randomization</LI>
<LI>Masking of intervention</LI>
<LI>Completeness of follow-up</LI>
<LI>Masking of outcome assessment</LI>
</OL>
<P>The possible answers to these questions could be: yes, no and can't tell.</P>
<P>Data from the primary author were obtained where published data provided inadequate information for the review or where relevant data could not be abstracted. Retrieved articles were assessed and data were abstracted independently by both review authors.</P>
<P>Statistical methods included calculation of relative risk (RR), risk difference (RD), number needed to treat (NNT) and weighted mean difference (WMD) when appropriate. Ninety five percent confidence intervals (CI) was used for these estimates of treatment effects. A fixed effect model was used for meta-analyses. Tests for between study heterogeneity including the I-squared (I<SUP>2</SUP>) test was applied.</P>
<P>Comparison included:</P>
<P>1. Any antistaphylococcal immunoglobulin preparations vs. placebo or no treatment</P>
<P>2. Different types of antistaphylococcal immunoglobulin preparations vs. placebo or no treatment</P>
<P>3. One type of antistaphylococcal immunoglobulin vs. another type of antistaphylococcal immunoglobulin preparation. Within each category subgroup, analyses are planned according to birth weight<BR/>a. among extremely low birth weight infants (&lt; 1000 g)<BR/>b. different types of immunoglobulin preparations</P>
<P>It is likely that these immunoglobulin preparations may have differential function depending upon their specificity against particular antigens.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-02-18 12:05:29 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-02-18 12:05:29 -0500" MODIFIED_BY="[Empty name]">
<P>A total of six reports eligible for inclusion were identified. Three reports have been published in an abstract form only. The authors of the three abstracts indicated that two studies have been submitted for publication and third would be submitted soon. As no further information other than what was available in the abstracts was provided, we have not abstracted the details of studies and have placed these studies in the section of studies awaiting further assessment (<LINK REF="STD-Weisman-2003" TYPE="STUDY">Weisman 2003</LINK> [trial details ClinicalTrials.gov Identifier: NCT00631878]; <LINK REF="STD-Weisman-2004" TYPE="STUDY">Weisman 2004</LINK>; <LINK REF="STD-Thackray-2006" TYPE="STUDY">Thackray 2006</LINK>).</P>
<P>A total of three reports are currently eligible for inclusion in this review (<LINK REF="STD-Benjamin-2006" TYPE="STUDY">Benjamin 2006</LINK>; <LINK REF="STD-Bloom-2005" TYPE="STUDY">Bloom 2005</LINK>; <LINK REF="STD-DeJonge-2007" TYPE="STUDY">DeJonge 2007</LINK>). Two studies (<LINK REF="STD-Bloom-2005" TYPE="STUDY">Bloom 2005</LINK>; <LINK REF="STD-DeJonge-2007" TYPE="STUDY">DeJonge 2007</LINK>) used pooled generic antistaphylococcal immunoglobulin (INH-A21) and the third study (<LINK REF="STD-Benjamin-2006" TYPE="STUDY">Benjamin 2006</LINK>) used antibody against type 5 and type 8 capsular polysachraide antigen (Altastaph). Clinical details regarding the participants, interventions and outcomes are given in the table "Characteristics of Included Studies" and are detailed below. Two studies (<LINK REF="STD-Capparelli-2005" TYPE="STUDY">Capparelli 2005</LINK>; <LINK REF="STD-Mandy-2000" TYPE="STUDY">Mandy 2000</LINK>) were excluded from the review and the reason for exclusion are reported in the table &#8220;Characteristics of Excluded Studies&#8221;.</P>
<P>
<LINK REF="STD-Benjamin-2006" TYPE="STUDY">Benjamin 2006</LINK> compared the effects of solution of IgG containing high concentrations of type 5 and type 8 capsular polysaccharide antigens of staphylococcal aureus (Altastaph) to placebo. This was a randomized controlled trial of 206 VLBW neonates from 18 NICUs. The infants were randomized to two groups: Group 1: received up to two doses of 1000 mg/kg (20 ml/kg) on study days 1 and 14; Group 2: received placebo in the form of 0.45% saline at similar volume and interval. All infusions were administered over 3 - 5 hours. All patients were followed for up to 28 days after second infusion or until discharge from nursery or death. The primary outcome was safety as assessed by proportion of neonates with adverse events and serious adverse events including mortality, hypoglycemia, and hypertension. Secondary outcomes included invasive Staphylococcal aureus infection (positive culture from sterile body fluid), definitive coagulase negative staphylococcal (CoNS) infection (two positive cultures on the same day or three or more positive cultures in <U>&lt;</U> 5 days), probable CoNS infection (two positive cultures in <U>&lt;</U> 5 days) and possible CoNS infection (one positive culture from sterile body fluid or positive cultures separated by &gt; 5 days). All patients were monitored for potential side effects (hypertension, hypoglycemia or glucose instability, respiratory compromise, discontinuation of infusion due to adverse effects) and common neonatal morbidities (PDA, NEC or gastrointestinal perforation).</P>
<P>
<LINK REF="STD-Bloom-2005" TYPE="STUDY">Bloom 2005</LINK> compared the effects donor-selected antistaphylococcal human immunoglobulin INH-A21 (Veronate®) to placebo in a group sequential dose ranging randomized study. This was a randomized controlled trial of 512 neonates between 501 to 1250g birth weight. Of these 512 neonates, 505 infants received at least one dose of study medication. The infants were randomized to four groups: Group 1: received up to four doses of 250 mg/kg/dose of INH-A21 on study days 1, 8, 22 and 36 provided intravenous access was available; Group 2: received up to four doses of 500 mg/kg/dose of INH-A21 on study days 1, 8, 22 and 36 provided intravenous access was available; Group 3: received up to four doses of 750 mg/kg/dose of INH-A21 on study days 1, 8, 22 and 36 provided intravenous access was available; Group 4: received placebo in the form of 0.45% saline at similar dose and interval. The volume for all doses was 15 ml/kg/dose. All infusions were administered according to dose escalation protocol. All patients were followed for up to 70 days after admission or until discharge home or to another institution or death. Investigators assessed at protocol-defined intervals efficacy and futility boundaries set by group-sequential bounds. It was planned that if a treatment effect of an arm crossed the futility boundary, randomization to that arm would stop and the remaining patients were to be enrolled in the subsequent treatment arms. This resulted in imbalance. For the purpose of this review, data from all three intervention groups were combined as the treatment group. The primary outcome was incidences of adverse events and serious adverse events and proportion of neonates with late-onset sepsis. Sepsis was diagnosed when, in addition to clinical features, one positive culture was identified from usually sterile culture sites. However, for coagulase negative staphylococcal sepsis, positive culture from two sites obtained within 72 hours was required. Probable sepsis was diagnosed when only one positive culture was identified and infant received &gt; 4 days of antibiotics. All patients were monitored for potential side effects and common neonatal morbidities. These included anemia, hyperbilirubinemia, PDA, NEC, ROP, IVH, PVL, hydrocephalus and spontaneous intestinal perforation. Data on certain patient characteristics and outcomes (gestational age, birth weight, number of infants with culture proven bacterial infection, chronic lung disease at 28 days, incidences of medically and surgically treated PDA, incidences of stage 1, 2 and 3 NEC, grade 3 or 4 IVH, stage 3 or 4 ROP, incidence of ROP surgery, duration of antibiotic use, duration of vancomycin use and incidences of pulmonary edema, hypertension and hypoglycemia) were obtained by contacting Veronate study group at Inhibitex Inc.</P>
<P>
<LINK REF="STD-DeJonge-2007" TYPE="STUDY">DeJonge 2007</LINK> compared the effect of donor-selected antistaphylococcal human immunoglobulin INH-A21 (Veronate®) to placebo. This was a randomized controlled trial of 1983 VLBW neonates from 95 NICUs. The infants were randomized to 2 groups: Group 1: received up to four doses of 1.5 ml/kg (750 mg/kg) on study days 1, 3, 8 and 15 provided intravenous access was available; Group 2: received placebo in the form of 0.45% saline at similar volume and interval. All infusions were administered according to dose escalation protocol. All patients were followed for up to 70 days after admission or until discharge home or to another institution or death. The primary outcome was proportion of neonates with late-onset sepsis due to staphylococcal aureus. Sepsis was diagnosed when, in addition to clinical features, one positive culture was identified from usually sterile culture sites. However, for CoNS sepsis positive culture from two sites obtained within 24 hours was required. Probable sepsis was diagnosed when only one positive culture was identified and the infant received &gt; 4 days of antibiotics. All patients were monitored for potential side effects and common neonatal morbidities. These included anemia, hyperbilirubinemia, PDA, NEC, ROP, IVH, PVL, hydrocephalus and spontaneous intestinal perforation. Data on certain outcomes (number of infants with culture proven bacterial infection, chronic lung disease at 28 days, incidences of medically and surgically treated PDA, incidences of stage 2 and 3 NEC, grade 3 or 4 IVH, stage 3 or 4 ROP, incidence of ROP surgery, duration of antibiotic use, duration of vancomycin use and incidences of pulmonary edema, hypertension and hypoglycemia) were obtained by contacting the Veronate study group at Inhibitex Inc.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-02-18 10:59:14 -0500" MODIFIED_BY="[Empty name]">
<P>The methodological qualities of the reviewed studies are given in the table "Characteristics of Included Studies." The information was extracted from the published paper and by contacting investigators. All three included studies were of high methodological quality.</P>
<P>
<LINK REF="STD-Benjamin-2006" TYPE="STUDY">Benjamin 2006</LINK>: The study was described as blinded and randomized. Detailed information on methodological quality was provided by authors. The randomization was done centrally by computerized numbers. Allocation of eligible patients was concealed and placebo and study medication were identical in appearance and volume. Investigators were not aware of randomization. Masking of outcome assessment was maintained and the follow-up was complete. Patients were followed up for 42 days or discharge/transfer from NICU or mortality. This may have resulted in incomplete data for certain long-term outcomes. </P>
<P>
<LINK REF="STD-Bloom-2005" TYPE="STUDY">Bloom 2005</LINK>: The study was described as blinded and randomized. Detailed information on methodological quality was provided by authors. The randomization was done centrally by computerized numbers. Allocation of eligible patients was concealed and placebo and study medication were identical in appearances and volume and investigators were not aware of randomization. A total of 512 patients were randomized, but only 505 received at least one dose of the study medication. Authors have only reported on these 505 patients. Masking of outcome assessment was maintained. Patients were followed up for 70 days or discharge/transfer from NICU or mortality. This may have resulted in incomplete data for certain long-term outcomes.</P>
<P>
<LINK REF="STD-DeJonge-2007" TYPE="STUDY">DeJonge 2007</LINK>: The study was described as blinded and randomized. Detailed information on methodological quality was provided by authors. The randomization was done centrally by computerized numbers. Allocation of eligible patients was concealed and placebo and study medication were identical in appearances and volume and investigators were not aware of randomization. Masking of outcome assessment was maintained. Patients were followed up for 70 days or discharge/transfer from NICU or mortality. This may have resulted in incomplete data for certain long-term outcomes.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-02-18 11:02:07 -0500" MODIFIED_BY="[Empty name]">
<P>Two chemically and immunogenically different products have been compared in these three studies (two studies of INH A-21 and one study of Altastaph). Due to differences in the products, differences in their mechanism of action, differences in the host response to the products and differences in the population studied (lower mean birth weight and longer duration of hospitalization for patients in INH A-21 studies), we have not combined data from both these products together and reported them separately.</P>
<P>
<B>ANTISTAPHYLOCOCCAL IMMUNOGLOBULIN VS. PLACEBO OR NO TREATMENT (COMPARISON 1):</B>
</P>
<P>
<B>Primary outcomes:</B>
</P>
<P>All three studies reported results of infection as infection rate during the study period in their studies. None of the studies reported the outcome as infection/days of hospitalization or time to infection.<B> </B>
</P>
<P>
<B>Incidence of Staphylococcal infections after intervention (Outcome 1.1):</B>
<BR/>Any probable or definite CONS sepsis as defined in the original studies were included. When INH A-21 was compared to placebo there was no statistically significant difference in the risk of Staphylococcal infections (typical RR 1.07, 95% CI 0.94, 1.22). When Altastaph was compared to placebo there was no statistically significant difference in the risk of Staphylococcal infections (RR 0.86, 95% CI 0.32, 2.28).  </P>
<P>
<B>Incidence of other bacterial infection after intervention (Outcome 1.2):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of other bacterial infections (typical RR 0.87, 95% CI 0.72, 1.06). When Altastaph was compared to placebo there was no statistically significant difference in the risk of other bacterial infections (RR 0.93, 95% CI 0.53, 1.64).</P>
<P>
<B>Incidence of any infection after intervention (Outcome 1.3): </B>
<BR/>This outcome includes bacterial, fungal or viral infections. When INH A-21 was compared to placebo there was no statistically significant difference in the risk of any infection (typical RR 1.00, 95% CI 0.91, 1.09). When Altastaph was compared to placebo there was no statistically significant difference in the risk of any infection (RR 0.93, 95% CI 0.54, 1.62). </P>
<P>
<B>Mortality prior to discharge from NICU: </B>
</P>
<P>
<B>a. Infection related mortality (Outcome 1.4):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of mortality due to infections (RR 2.73, 95% CI 0.33, 22.50).</P>
<P>
<B>b. All cause mortality (Outcomes 1.5.1 and 1.5.2):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of mortality due to any cause (typical RR 0.80, 95% CI 0.59, 1.08). When Altastaph was compared to placebo there was no statistically significant difference in the risk of mortality due to any cause (RR 1.31, 95% CI 0.30, 5.70).</P>
<P>
<B>Secondary outcomes:</B>
</P>
<P>
<B>Chronic lung disease (Outcome 1.6):</B>
<BR/>Data on chronic lung disease were available from investigators of INH A-21 at 28 days only and not at 36 weeks postmenstrual age as defined in the current review. There was no statistically significant difference in the risk of chronic lung disease at 28 days between INH A-21 vs. placebo (typical RR 0.99, 95% CI 0.95, 1.04). </P>
<P>
<B>Patent ductus arteriosus (Outcome 1.7):</B>
<BR/>Between group treated with INH A-21 vs. group treated with placebo, there was no statistically significant difference in the risk of patent ductus arteriosus treated medically (typical RR 1.06, 95% CI 0.94, 1.19), patent ductus arteriosus treated surgically (typical RR 1.01, 95% CI 0.83, 1.22), patent ductus arteriosus treated medically or surgically (typical RR 1.04, 95% CI 0.96, 1.14). Between group treated with Altastaph vs. group treated with placebo there was no statistically significant difference in the risk of patent ductus arteriosus (RR 0.98, 95% CI 0.0.46, 2.08).</P>
<P>
<B>Necrotizing enterocolitis (Outcome 1.8):</B>
<BR/>Between group treated with INH A-21 vs. group treated with placebo, there was no statistically significant difference in the risk of stage 1 NEC (RR 0.63, 95% CI 0.26, 1.53), stage 2 NEC (typical RR 1.00, 95% CI 0.73, 1.38) or stage 3 NEC (typical RR 0.80, 95% CI 0.46, 1.40). Between group treated with Altastaph vs. group treated with placebo there was no statistically significant difference in the risk of NEC or gastrointestinal perforation (combined outcome reported not pre-specified in the protocol of this review) (RR 1.37, 95% CI 0.45, 4.19).</P>
<P>
<B>Intraventricular hemorrhage (Outcome 1.9):</B>
</P>
<P>
<B>a. Any grade of intraventricular hemorrhage (Outcomes 1.1.1 and 1.1.2):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of any grade of intraventricular hemorrhage (typical RR 0.93, 95% CI 0.83, 1.04). When Altastaph was compared to placebo there was no statistically significant difference in the risk of any grade of intraventricular hemorrhage (RR 0.75, 95% CI 0.35, 1.25).</P>
<P>
<B>b. Grade 3 or grade 4 intraventricular hemorrhage (Outcome 1.9.3):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of grade 3 or 4 intraventricular hemorrhage (typical RR 0.98, 95% CI 0.77, 1.25).</P>
<P>
<B>Periventricular leukomalacia (Outcome 1.10): </B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of periventricular leukomalacia (typical RR 1.11, 95% CI 0.74, 1.65).</P>
<P>
<B>Retinopathy of prematurity (Outcome 1.11):</B>
</P>
<P>
<B>a. Any stage of retinopathy of prematurity (Outcome 1.11.1):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of any stage of retinopathy of prematurity (typical RR 1.00, 95% CI 0.91, 1.10).</P>
<P>
<B>b. Stage 3 or 4 retinopathy of prematurity (Outcome 1.11.2):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of Stage 3 or 4 retinopathy prematurity (typical RR 0.81, 95% CI 0.59, 1.10).</P>
<P>
<B>Length of hospitalization (in days):</B>
<BR/>None of the studies has reported on this outcome.</P>
<P>
<B>Neurodevelopmental disability at 18 - 24 months:</B>
</P>
<P>None of the studies has reported on this outcome.</P>
<P>
<B>Change in the titre of antistaphylococcal antibody levels:</B>
<BR/>
<LINK REF="STD-Benjamin-2006" TYPE="STUDY">Benjamin 2006</LINK> reported on antibody titre and showed a significant increase in the antibody titre through out the study period in the Altastaph group and no detectable antibody levels in the placebo group.</P>
<P>
<B>Incidences of allergic reaction (skin rash, anaphylaxis) (Outcome 1.14):</B>
<BR/>There was no allergic reactions noted in either group in studies by <LINK REF="STD-Bloom-2005" TYPE="STUDY">Bloom 2005</LINK> and <LINK REF="STD-DeJonge-2007" TYPE="STUDY">DeJonge 2007</LINK>).</P>
<P>
<B>Incidence of transmission of blood borne disease:</B>
<BR/>None of the studies has reported on this outcome.</P>
<P>
<B>Duration of any antibiotic use prior to discharge (days) (Outcome 1.12):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the duration of antibiotic use (WMD 0.02 days, 95% CI -1.15 days, 1.19 days).</P>
<P>
<B>Duration of Vancomycin use prior to discharge (days) (Outcome 1.13):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the duration of Vancomycin use (WMD 0.05 days, 95% CI -0.68 days, 0.78 days).</P>
<P>
<B>Clinically important adverse effects reported by authors:</B>
</P>
<P>
<B>a. Pulmonary edema (Outcome 1.15): </B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of pulmonary edema (typical RR 1.46, 95% CI 0.94, 2.26).</P>
<P>
<B>b . Hypertension (Outcome 1.16.1 and 1.16.2):</B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of hypertension (typical RR 1.16, 95% CI 0.84, 1.61). When Altastaph was compared to placebo there was no statistically significant difference in the risk of hypertension (RR 1.47, 95% CI 0.63, 3.45).</P>
<P>
<B>c. Hypoglycemia (Outcome 1.17.1 and 1.17.2): </B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of hypoglycemia (typical RR 1.15, 95% CI 0.90, 1.47). When Altastaph was compared to placebo there was no statistically significant difference in the risk of hypoglycemia (RR 1.40, 95% CI 0.55, 3.54).</P>
<P>
<B>Any clinically important outcome or adverse effects reported by authors (not pre-specified) (Outcome 1.18):</B>
</P>
<P>
<B>a. Discontinuation of study medication due to adverse events (Outcome 1.18.1 and 1.18.2): </B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of discontinuation of study medication due to adverse events (RR 0.68, 95% CI 0.25, 1.89). When Altastaph was compared to placebo there was no statistically significant difference in the risk of discontinuation of study medication due to adverse events (RR 1.18, 95% CI 0.37, 3.74).</P>
<P>
<B>b. Serious adverse events (Outcomes 1.18.3 and 1.18.4): </B>
<BR/>When INH A-21 was compared to placebo there was no statistically significant difference in the risk of serious adverse events (RR 1.04, 95% CI 0.72, 1.51). When Altastaph was compared to placebo there was no statistically significant difference in the risk of serious adverse events (RR 1.18, 95% CI 0.37, 3.74).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-02-18 11:16:28 -0500" MODIFIED_BY="[Empty name]">
<P>Three different pharmacological agents of antistaphylococcal immunoglobulins have been tested for prevention of staphylococcal infections in VLBW neonates. Results of two of these agents (INH A-21 and Altastaph) are published. The results of the trials of Pagibaximab have been published as abstracts and are awaiting full publication. Of the three studies included in this review, two were Phase II trials (one of INH A-21 and one trial of Altastaph) and one for INH A21 was a Phase III trial of adequate sample size. Analyses of these agents failed to demonstrate any significant difference in any of the primary or secondary outcomes of this review. There was no reduction in the risk of infections (staphylococcal or non-staphylococcal), mortality or important secondary outcomes related to VLBW infants. Only preliminary reports of Pagibaximab (<LINK REF="STD-Thackray-2006" TYPE="STUDY">Thackray 2006</LINK>; <LINK REF="STD-Weisman-2003" TYPE="STUDY">Weisman 2003</LINK>; <LINK REF="STD-Weisman-2004" TYPE="STUDY">Weisman 2004</LINK>) are available and based on these results, a plan for phase II/III trials is underway (<LINK REF="REF-Weisman-2007" TYPE="REFERENCE">Weisman 2007</LINK>).</P>
<P>Efforts have been made to boost the level of circulating immunoglobulins in preterm and very low birth weight infants due to the low levels of IgG antibodies at birth and the anticipated decline of immunoglobulins in the first 4 - 8 weeks after birth. Standard IVIG reduced sepsis by 3% without any other benefits. Our review failed to identify benefits of specific hyperimmune globulins against staphylococci. However, these results are from two preliminary trials (one of dose finding and another of establishing safety) and only one phase three study. The products studied are also quite dissimilar in their mechanisms of action. Studies of INH A-21 (<LINK REF="STD-Bloom-2005" TYPE="STUDY">Bloom 2005</LINK>; <LINK REF="STD-DeJonge-2007" TYPE="STUDY">DeJonge 2007</LINK>) enrolled smaller and more immature neonates and followed them for a longer period of time (72 days) compared to study of Altastaph (<LINK REF="STD-Benjamin-2006" TYPE="STUDY">Benjamin 2006</LINK>), where infants were more mature and studied for 42 days. This may have an important effect on the results as the risk of infection is greater in smaller more immature infants and the chance of finding an infection increases the longer the subjects are followed. None of the studies reported the incidence of infection as a function of time (in the unit of per 1000 admissions or as per 1000 days of study or hospitalization) so one could not directly compare results in a standardized fashion. It is also unclear from the description of studies whether a single neonate who had multiple infections were counted more than once. Suggested definition of definitive infection include signs of sepsis and two positive cultures obtained from blood or normally sterile body fluids within 24 hours. This is not consistent among included studies and may have affected results. These are important features that need to be understood in the context of future clinical trials.</P>
<P>Important components of the immune system in addition to opsonizing antibody include complement, phagocyte signalling and function, and cytokines. Antibodies interact with complement and phagocytic cells and in preterm infants and complement levels and toll-like receptors are lower compared to full term infants and adults (<LINK REF="REF-Strunk-2007" TYPE="REFERENCE">Strunk 2007</LINK>). Phagocytic cells including neutrophils, monocytes and macrophages have diminished function of chemotaxis, adherence, activation, phagocytosis, the oxidative burst and release of antimicrobial products in the phagosome. These functions may be critical after interaction with antibody and complement and may partially explain the lack of efficacy in these antibody products in the preterm infant. As these components work in concert leading to phagocytosis and lysis of microbes, successful preventative therapies in an immunocompromised host may involve more than an antibody approach.</P>
<P>From these studies some observations can be made. While antibody levels are low during the time period, the underdeveloped immune system of the preterm infant may need more than one component to aid its defense against systemic infection. It is unknown whether different antibodies or a combination of these and other immune factors would be efficacious in the prevention of staphylococcal infections. All these studies lacked appropriate animal models similar to the preterm host. None of the antibody preparations were tested in immunocompromised animal models. Research in this area would help to answer unknown questions regarding efficacy of specific antibody preparations prior to the onset of further human clinical trials. In addition, the role of cytokines, colony stimulating factors, complement and other components of the immune system working in concert with antibodies in attenuating colonization, proliferation and invasive infection of these micro-organisms in the preterm infant can be ascertained.</P>
<P>Based on findings of this review, we can conclude that antistaphylococcal immunoglobulins in the forms of INH A-21 and Altastaph revealed no significant effects, either benefits or risks, when used for prevention of staphylococcal infections in VLBW preterm neonates.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-09-12 10:08:09 -0400" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-09-12 10:08:09 -0400" MODIFIED_BY="[Empty name]">
<P>This review of two preliminary trials and one definitive trials identified no significant effects, either benefits or risks, of the antistaphylococcal immunoglobulin preparations INH A-21 or Altastaph, for the prevention of staphylococcal infections in very low birth-weight infants. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-02-04 11:30:29 -0500" MODIFIED_BY="[Empty name]">
<P>Further research to investigate the efficacy of other products such as Pagibaximab may reveal efficacy and safety profile appropriate for neonates.  Preterm or immunocompromised animal models are needed to evaluate efficacy of new products or combination therapies.  Additionally, adjunctive therapy augmenting neutrophil and monocyte function may be needed for antibody preparations to have efficacy in preterm infants.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-01-17 14:59:59 -0500" MODIFIED_BY="[Empty name]">
<P>We would like to thank investigator group at Inhibitex Corp. for providing results of their studies for certain outcomes.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-01-30 13:04:45 -0500" MODIFIED_BY="[Empty name]">
<P>Dr Kaufman was investigator for <LINK REF="STD-Bloom-2005" TYPE="STUDY">Bloom 2005</LINK>; <LINK REF="STD-Benjamin-2006" TYPE="STUDY">Benjamin 2006</LINK> and <LINK REF="STD-DeJonge-2007" TYPE="STUDY">DeJonge 2007</LINK> studies.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-02-04 11:31:02 -0500" MODIFIED_BY="[Empty name]">
<P>
<BR/>P Shah<BR/>Writing of the protocol and review<BR/>Editing of the protocol and review</P>
<P>Data collection and data check</P>
<P>D Kaufman<BR/>Editing and review of the protocol and review</P>
<P>Data collection and data check</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-09-12 10:10:03 -0400" MODIFIED_BY="[Empty name]">
<P>Two chemically and immunogenically different products have been compared in three included studies of this review (two studies of INH A-21 and one study of Altastaph). Due to the variability in the products, their mechanisms of action and difference in the host responses to them, and differences in the population studied (lower mean birth weight and longer duration of hospitalization for patients in INH A-21 studies) we have not combined data from both these products together as mentioned in the protocol but we have reported them separately.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-21 15:51:43 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-02-15 11:01:32 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-02-15 11:01:32 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Benjamin-2006" MODIFIED="2008-02-15 11:01:19 -0500" MODIFIED_BY="[Empty name]" NAME="Benjamin 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-02-15 11:01:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benjamin DK, Schelonka R, White R, Holley HP, Bifano E, et al</AU>
<TI>A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin</TI>
<SO>Journal of Perinatology</SO>
<YR>2006</YR>
<VL>26</VL>
<PG>290-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bloom-2005" MODIFIED="2008-02-15 11:01:24 -0500" MODIFIED_BY="[Empty name]" NAME="Bloom 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-02-15 11:01:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bloom B, Schelonka R, Kueser T, Walker W, Jung E, Kaufman D, et al</AU>
<TI>Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants</TI>
<SO>The Pediatric Infectious Disease Journal</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>10</NO>
<PG>858-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-DeJonge-2007" MODIFIED="2008-02-15 11:01:32 -0500" MODIFIED_BY="[Empty name]" NAME="DeJonge 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-02-15 11:01:32 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, et al</AU>
<TI>Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>2007</YR>
<VL>151</VL>
<PG>260-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-01-11 09:56:49 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Capparelli-2005" MODIFIED="2008-01-11 09:30:23 -0500" MODIFIED_BY="[Empty name]" NAME="Capparelli 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-01-11 09:30:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Capparelli EV, Bloom BT, Kueser TJ, Oelberg DG, Bifano EM, White RD, et al</AU>
<TI>Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2005</YR>
<VL>49</VL>
<PG>4121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mandy-2000" MODIFIED="2008-01-11 09:56:49 -0500" MODIFIED_BY="[Empty name]" NAME="Mandy 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-01-11 09:56:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mandy GT, Weisman LE, Horwith G, Fuller S, Fanaroff AA</AU>
<TI>Safety of a Staphylococcus Aureus (SA) Intravenous Human Immune Globulin (AltaStaph) in Very-Low-Birth-Weight (VLBW) Neonates</TI>
<SO>Pediatric Research</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-01-11 09:53:58 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Thackray-2006" MODIFIED="2008-01-11 09:53:58 -0500" MODIFIED_BY="[Empty name]" NAME="Thackray 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-01-11 09:53:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thackray H, Lassiter H, Walsh W, Brozanski B, Steinhorn R, Dhanireddy R, et al</AU>
<TI>Phase II Randomized, Double Blind, Placebo-Controlled, Safety, Pharmacokinetics (PK), and Clinical Activity Study in Very Low Birth Weight (VLBW) Neonates of Pagibaximab, a Monoclonal Antibody for the Prevention of Staphylococcal Infection</TI>
<SO>Pediatric Research E-PAS</SO>
<YR>2006</YR>
<VL>59</VL>
<PG>3724.6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisman-2003" MODIFIED="2008-01-11 09:49:19 -0500" MODIFIED_BY="[Empty name]" NAME="Weisman 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-01-11 09:49:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weisman LE, Mandy GT, Garcia-Prats JA, Nesin M, Schneider JH, Johnson KE, et al</AU>
<TI>Safety and Pharmacokinetics of a Human Chimeric Anti-Staphylococcal Monoclonal Antibody for Prevention of Coagulase Negative Staphylococcal Infection in Very Low Birth Weight Infants: Preliminary Report</TI>
<SO>Pediatric Research</SO>
<YR>2003</YR>
<VL>53</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weisman-2004" MODIFIED="2008-01-11 09:44:08 -0500" MODIFIED_BY="[Empty name]" NAME="Weisman 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-01-11 09:43:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weisman LE, Thackray HM, Gracia-Prats JA, Nesin M, Mond J, Schneider JH, et al</AU>
<TI>Phase I/II Double Blind, Placebo Controlled, Dose Escalation, Safety and Pharmacokinetics Study in Very Low Birth Weight Neonates of BSYX-A110, an Anti-Staphylococcal Monoclonal Antibody for the Prevention of Staphylococcal Bloodstream Infections</TI>
<SO>Pediatric Research</SO>
<YR>2004</YR>
<VL>55</VL>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-21 15:51:43 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-21 15:51:43 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams_x002d_Chapman-2006" MODIFIED="2008-02-04 15:48:43 -0500" MODIFIED_BY="[Empty name]" NAME="Adams-Chapman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Adams-Chapman I, Stoll BJ</AU>
<TI>Neonatal infection and long-term neurodevelopmental outcome in the preterm infant</TI>
<SO>Current Opinion in Infectios Diseases</SO>
<YR>2006</YR>
<VL>19</VL>
<PG>290-7</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:48:43 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Banerjea-2002" MODIFIED="2008-02-04 15:51:41 -0500" MODIFIED_BY="[Empty name]" NAME="Banerjea 2002" TYPE="JOURNAL_ARTICLE">
<AU>Banerjea MC, Speer CP</AU>
<TI>The current role of colony-stimulating factors in prevention and treatment of neonatal sepsis</TI>
<SO>Seminars in Neonatology</SO>
<YR>2002</YR>
<VL>7</VL>
<PG>335-49</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:51:41 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Bell-1978" NAME="Bell 1978" TYPE="JOURNAL_ARTICLE">
<AU>Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L et al</AU>
<TI>Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging</TI>
<SO>Annals of Surgery</SO>
<YR>1978</YR>
<VL>187</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Capparelli-2005" MODIFIED="2008-02-04 15:48:25 -0500" MODIFIED_BY="[Empty name]" NAME="Capparelli 2005" NOTES="&lt;p&gt;DA - 20050928&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:48:25 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Capparelli EV, Bloom BT, Kueser TJ, Oelberg DG, Bifano EM, White RD, et al</AU>
<TI>Multicenter study to determine antibody concentrations and assess the safety of administration of INH-A21, a donor-selected human Staphylococcal immune globulin, in low-birth-weight infants</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2005</YR>
<VL>49</VL>
<PG>4121-7</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:48:25 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Conner-2004" MODIFIED="2008-10-21 15:51:43 -0400" MODIFIED_BY="[Empty name]" NAME="Conner 2004" NOTES="&lt;p&gt;DA - 20040219&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 15:51:43 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Conner JM, Soll RF, Edwards WH</AU>
<TI>Topical ointment for preventing infection in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-21 15:51:43 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 15:51:43 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001150.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fanaroff-1998" MODIFIED="2008-02-04 15:49:17 -0500" MODIFIED_BY="[Empty name]" NAME="Fanaroff 1998" NOTES="&lt;p&gt;DA - 19980929&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:49:17 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Fanaroff AA, Korones SB, Wright LL, Verter J, Poland RL, Bauer CR, et al</AU>
<TI>Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>593-8</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:49:17 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Graham-2004" MODIFIED="2008-02-04 15:49:33 -0500" MODIFIED_BY="[Empty name]" NAME="Graham 2004" NOTES="&lt;p&gt;DA - 20041027&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:49:33 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Graham EM, Holcroft CJ, Rai KK, Donohue PK, Allen MC</AU>
<TI>Neonatal cerebral white matter injury in preterm infants is associated with culture positive infections and only rarely with metabolic acidosis</TI>
<SO>American Journal of Obstetric and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<PG>1305-10</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:49:33 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gray-1995" MODIFIED="2008-02-04 15:49:45 -0500" MODIFIED_BY="[Empty name]" NAME="Gray 1995" NOTES="&lt;p&gt;DA - 19950227&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:49:45 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Gray JE, Richardson DK, McCormick MC, Goldmann DA</AU>
<TI>Coagulase-negative staphylococcal bacteremia among very low birth weight infants: relation to admission illness severity, resource use, and outcome</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>95</VL>
<PG>225-30</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:49:45 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Horbar-2001" MODIFIED="2008-02-04 15:50:06 -0500" MODIFIED_BY="[Empty name]" NAME="Horbar 2001" NOTES="&lt;p&gt;DA - 20010108&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:50:06 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Horbar JD, Rogowski J, Plsek PE, Delmore P, Edwards WH, Hocker J, et al</AU>
<TI>Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network</TI>
<SO>Pediatrics</SO>
<YR>2001</YR>
<VL>107</VL>
<PG>14-22</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:50:06 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kaufman-2004" MODIFIED="2008-02-04 15:50:31 -0500" MODIFIED_BY="[Empty name]" NAME="Kaufman 2004" NOTES="&lt;p&gt;DA - 20040719&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:50:31 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman D, Fairchild KD</AU>
<TI>Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants</TI>
<SO>Clinical Microbiological Review</SO>
<YR>2004</YR>
<VL>17</VL>
<PG>638-80</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:50:31 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kaufman-2006" MODIFIED="2008-02-04 15:50:40 -0500" MODIFIED_BY="[Empty name]" NAME="Kaufman 2006" NOTES="&lt;p&gt;DA - 20060227&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:50:40 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman D</AU>
<TI>Veronate (Inhibitex)</TI>
<SO>Current Opinion on Investigational Drugs</SO>
<YR>2006</YR>
<VL>7</VL>
<PG>172-9</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:50:40 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Ohlsson-2004" MODIFIED="2008-10-21 15:49:19 -0400" MODIFIED_BY="[Empty name]" NAME="Ohlsson 2004" NOTES="&lt;p&gt;DA - 20040219&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 15:49:19 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Ohlsson A, Lacy JB</AU>
<TI>Intravenous immunoglobulin for suspected or subsequently proven infection in neonates</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-21 15:49:19 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 15:49:19 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001239.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ohlsson-2004a" MODIFIED="2008-10-21 15:50:31 -0400" MODIFIED_BY="[Empty name]" NAME="Ohlsson 2004a" NOTES="&lt;p&gt;DA - 20040219&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 15:50:31 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Ohlsson A, Lacy JB</AU>
<TI>Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-10-21 15:50:31 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 15:50:31 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000361.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Papile-1978" NAME="Papile 1978" TYPE="JOURNAL_ARTICLE">
<AU>Papile LA, Burstein J, Burstein R, Koffler H</AU>
<TI>Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm</TI>
<SO>Journal of Pediatrics</SO>
<YR>1978</YR>
<VL>92</VL>
<PG>529-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Patti-2005" NAME="Patti 2005" NOTES="&lt;p&gt;DA - 20051214&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Patti JM</AU>
<TI>Vaccines and immunotherapy for staphylococcal infections</TI>
<SO>International Journal of Artificial Organs</SO>
<YR>2005</YR>
<VL>28</VL>
<PG>1157-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schroeder-1995" NAME="Schroeder 1995" NOTES="&lt;p&gt;DA - 19951204&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Schroeder HW, Jr., Mortari F, Shiokawa S, Kirkham PM, Elgavish RA, Bertrand FE 3rd</AU>
<TI>Developmental regulation of the human antibody repertoire</TI>
<SO>Annals of New York Academy of Science</SO>
<YR>1995</YR>
<VL>764</VL>
<PG>242-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shennan-1988" NAME="Shennan 1988" TYPE="JOURNAL_ARTICLE">
<AU>Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM</AU>
<TI>Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period</TI>
<SO>Pediatrics</SO>
<YR>1988</YR>
<VL>82</VL>
<PG>527-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Singh_x002d_Grewal-2006" NAME="Singh-Grewal 2006" TYPE="JOURNAL_ARTICLE">
<AU>Singh-Grewal D, Kemp A, Wong M</AU>
<TI>A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions</TI>
<SO>Archives of Disease of Childhood</SO>
<YR>2006</YR>
<VL>91</VL>
<PG>651-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Splawski-1991" MODIFIED="2008-02-04 15:50:56 -0500" MODIFIED_BY="[Empty name]" NAME="Splawski 1991" NOTES="&lt;p&gt;DA - 19910311&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:50:56 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Splawski JB, Jelinek DF, Lipsky PE</AU>
<TI>Delineation of the functional capacity of human neonatal lymphocytes</TI>
<SO>Journal of Clinical Investigations</SO>
<YR>1991</YR>
<VL>87</VL>
<PG>545-53</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:50:56 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Stoll-2002" NAME="Stoll 2002" NOTES="&lt;p&gt;DA - 20020807&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al</AU>
<TI>Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network</TI>
<SO>Pediatrics</SO>
<YR>2002</YR>
<VL>110</VL>
<PG>285-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stoll-2004" NAME="Stoll 2004" NOTES="&lt;p&gt;DA - 20041119&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, et al</AU>
<TI>Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2004</YR>
<VL>292</VL>
<PG>2357-65</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Strunk-2007" MODIFIED="2008-02-04 11:27:25 -0500" MODIFIED_BY="[Empty name]" NAME="Strunk 2007" TYPE="JOURNAL_ARTICLE">
<AU>Strunk T, Richmond P, Simmer K, Currie A, Levy O, Burgner D</AU>
<TI>Neonatal immune responses to coagulase-negative staphylococci</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>4</NO>
<PG>370-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vernachio-2006" MODIFIED="2008-02-04 15:51:10 -0500" MODIFIED_BY="[Empty name]" NAME="Vernachio 2006" NOTES="&lt;p&gt;DA - 20060126&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:51:10 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Vernachio JH, Bayer AS, Ames B, Bryant D, Prater BD, Syribeys PJ, Gorovits EL, Patti JM</AU>
<TI>Human immunoglobulin G recognizing fibrinogen-binding surface proteins is protective against both Staphylococcus aureus and Staphylococcus epidermidis infections in vivo</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2006</YR>
<VL>50</VL>
<PG>511-8</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:51:10 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Weisman-1994" MODIFIED="2008-02-04 15:51:19 -0500" MODIFIED_BY="[Empty name]" NAME="Weisman 1994" NOTES="&lt;p&gt;DA - 19950420&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:51:19 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Weisman LE, Cruess DF, Fischer GW</AU>
<TI>Opsonic activity of commercially available standard intravenous immunoglobulin preparations</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1994</YR>
<VL>13</VL>
<PG>1122-5</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:51:19 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Weisman-2004" MODIFIED="2008-02-04 15:51:28 -0500" MODIFIED_BY="[Empty name]" NAME="Weisman 2004" NOTES="&lt;p&gt;DA - 20040528&lt;/p&gt;" NOTES_MODIFIED="2008-02-04 15:51:28 -0500" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Weisman LE</AU>
<TI>Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient</TI>
<SO>Current Opinion in Infectious Diseases</SO>
<YR>2004</YR>
<VL>17</VL>
<PG>237-41</PG>
<IDENTIFIERS MODIFIED="2008-02-04 15:51:28 -0500" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Weisman-2007" MODIFIED="2008-01-17 14:49:00 -0500" MODIFIED_BY="[Empty name]" NAME="Weisman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Weisman LE</AU>
<TI>Antibody for teh prevention of neonatal nosocomial staphylococcal infection: a review of the literature</TI>
<SO>Archives de Pediatrie</SO>
<YR>2007</YR>
<VL>14</VL>
<PG>S31-S34</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-05-19 08:31:08 -0400" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-05-19 08:31:08 -0400" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-01-30 13:03:36 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benjamin-2006">
<CHAR_METHODS MODIFIED="2008-01-30 13:03:36 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial.</P>
<P>Masking of randomization - yes</P>
<P>Masking of intervention - yes</P>
<P>Masking of outcome assessment - yes</P>
<P>Completeness of follow up - yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-11 10:51:58 -0500" MODIFIED_BY="[Empty name]">
<P>206 VLBW neonates from 18 NICUs.</P>
<P>Group 1: Median (SD) BW 1018 (269) grams</P>
<P>Male: Female - 57:57</P>
<P>Group 2: Median (SD) BW 1055 (268) grams</P>
<P>Male: Female - 56:56</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-01-11 10:52:15 -0500" MODIFIED_BY="[Empty name]">
<P>Group 1: received up to two doses of 1000 mg/Kg (20 ml/Kg) on study days 1 and 14; Group 2: received placebo in the form of 0.45% saline at similar dose and interval.</P>
<P>All infusions were administered over 3-5 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-11 11:19:14 -0500" MODIFIED_BY="[Empty name]">
<P>Safety as assessed by proportion of neonates with adverse events and serious adverse events including mortality, hypoglycemia, and hypertension, Discontinuation of infusion due to adverse effects, Respiratory compromise, hypoglycemia, hypertension, glucose instability, gastrointestinal perforation were reported. efficacy outcomes included Invasive Staphylococcal aureus infection, Definitive CoNS infection, </P>
<P>Probable CoNS infection and Possible CoNS infection.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-01-11 10:52:58 -0500" MODIFIED_BY="[Empty name]">
<P>All patients were followed for up to 28 days after second infusion or until discharge from nursery or death.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-19 08:31:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bloom-2005">
<CHAR_METHODS MODIFIED="2008-01-11 10:59:45 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>I. Masking of randomization - yes<BR/>II. Masking of intervention - yes<BR/>III. Masking of outcome assessment - yes<BR/>IV. Completeness of follow up ? no</P>
<P>V. Intention to treat analyses: No</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-11 11:08:20 -0500" MODIFIED_BY="[Empty name]">
<P>A total of 512 neonates &lt;1250g BW were randomized from 20 NICUs.</P>
<P>505 patients received one dose of study medication</P>
<P>Group 1: Mean (SD) BW 920 (202) grams; Mean (SD) GA 26.9 (2.0) weeks; Male: Female - 47:47</P>
<P>Group 2: Mean (SD) BW 889 (204) grams; Mean (SD) GA 26.6 (2.0) weeks; Male: Female - 49:47</P>
<P>Group 3: Mean (SD) BW 909 (179) grams; Mean (SD) GA 27.1 (2.4) weeks; Male: Female - 85:72</P>
<P>Group 4: Mean (SD) BW 900 (190) grams; Mean (SD) GA 26.9 (2.0) weeks; Male: Female - 71:87</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-19 08:31:08 -0400" MODIFIED_BY="[Empty name]">
<P>Group 1: received up to four doses of 250 mg/kg/dose of INH-A21</P>
<P>Group 2: received up to four doses of 500 mg/kg/dose of INH-A21</P>
<P>Group 3: received up to four doses of 750 mg/kg/dose of INH-A21 </P>
<P>Group 4: received placebo in the form of 0.45% saline at similar dose and interval</P>
<P>All study medications were given on study days 1, 8, 22 and 36 provided intravenous access was available. The volume for all doses was 15 ml/kg/dose. All infusions were administered according to dose escalation protocol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-11 11:05:56 -0500" MODIFIED_BY="[Empty name]">
<P>Data on outcomes reported in the publication were Sepsis, CoNS sepsis, Probable CoNS sepsis, Anemia, Hyperbilirubinemia, PDA, NEC, ROP, IVH, PVL, Hydrocephalus, and Spontaneous intestinal perforation. </P>
<P>Data on outcomes of culture proven bacterial infection, Chronic lung disease at 28 days, Incidences of medically and surgically treated PDA, Incidences of stage 1, 2 and 3 NEC, Grade 3 or 4 IVH, Stage 3 or 4 ROP, Incidence of ROP surgery, Duration of antibiotic use Duration of vancomycin use, Incidences of pulmonary edema, hypertension and hypoglycemia were obtained by contacting authors</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-01-11 11:06:13 -0500" MODIFIED_BY="[Empty name]">
<P>All patients were followed for up to 70 days after admission, or until discharge home or to another institution or death.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-01-11 11:16:29 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DeJonge-2007">
<CHAR_METHODS MODIFIED="2008-01-11 11:09:05 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>I. Masking of randomization - yes<BR/>II. Masking of intervention - yes<BR/>III. Masking of outcome assessment - yes<BR/>IV. Completeness of follow up - yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-11 11:10:06 -0500" MODIFIED_BY="[Empty name]">
<P>A total of 1983 VLBW neonates from 95 NICUs.</P>
<P>Group 1: Mean (SD) BW 891 (204) grams; Mean (SD) GA 26.8 (2.2) weeks; Male: Female - 487:507</P>
<P>Group 2: Mean (SD) BW 896 (197) grams; Mean (SD) GA 26.8 (2.2) weeks; Male: Female - 504:485</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-01-11 11:10:25 -0500" MODIFIED_BY="[Empty name]">
<P>Group 1: received up to four doses of 1.5 ml/Kg (750 mg/Kg) on study days 1, 3, 8 and 15 provided intravenous access was available;</P>
<P>Group 2: received placebo in the form of 0.45% saline at similar dose and interval. All infusions were administered according to dose escalation protocol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-11 11:16:29 -0500" MODIFIED_BY="[Empty name]">
<P>Data on the outcomes reported in the publication were late-onset sepsis by staphylococcal aureus, CoNS</P>
<P>Probable infection, Anemia, Hyperbilirubinemia, PDA, NEC, ROP, IVH, PVL, Hydrocephalus, and Spontaneous intestinal perforation.</P>
<P>Data on outcomes of infants with culture proven bacterial infection, chronic lung disease at 28 days, incidences of medically and surgically treated PDA, incidences of stage 2 and 3 NEC, grade 3 or 4 IVH, stage 3 or 4 ROP, incidence of ROP surgery, duration of antibiotic use, duration of vancomycin use and incidences of pulmonary edema, hypertension, and hypoglycemia were obtained from the authors.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-01-11 11:13:30 -0500" MODIFIED_BY="[Empty name]">
<P>All patients were followed for up to 70 days after admission, or until discharge home or to another institution or death.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>SD = standard deviation, BW = birth weight, GA = gestational age, PDA = patent ductus arteriosus, NEC = necrotizing enterocolitis, ROP = retinapathy of prematurity, IVH = intraventricular hemorrhage, PVL = periventricular leukomalacia, CoNS infection = Coagulase negative staphylococcal infection</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-01-11 22:46:18 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-01-11 22:45:00 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Capparelli-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-01-11 22:45:00 -0500" MODIFIED_BY="[Empty name]">
<P>Phase 1 open label dose escalation study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-01-11 22:46:18 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mandy-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-01-11 22:46:18 -0500" MODIFIED_BY="[Empty name]">
<P>No comparative group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-01-11 22:56:02 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2008-01-11 22:54:09 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thackray-2006">
<CHAR_METHODS MODIFIED="2008-01-11 22:47:33 -0500" MODIFIED_BY="[Empty name]">
<P>Phase 2 double blind randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-11 22:47:48 -0500" MODIFIED_BY="[Empty name]">
<P>Very Low Birth Weight neonates</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-01-11 22:48:19 -0500" MODIFIED_BY="[Empty name]">
<P>Pagibaximab or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-11 22:48:41 -0500" MODIFIED_BY="[Empty name]">
<P>Safety, pharmacokinetics, pharmacodynamics, clinical activity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-01-11 22:54:09 -0500" MODIFIED_BY="[Empty name]">
<P>Abstract only, authors were contacted and advised that the report was under consideration for publication, no further details were provided</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-01-11 22:56:02 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weisman-2003">
<CHAR_METHODS MODIFIED="2008-01-11 22:55:12 -0500" MODIFIED_BY="[Empty name]">
<P>Safety and pharmacokinetic study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-11 22:55:22 -0500" MODIFIED_BY="[Empty name]">
<P>Very Low Birth Weight neonates</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-01-11 22:55:35 -0500" MODIFIED_BY="[Empty name]">
<P>Pagibaximab </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-11 22:55:48 -0500" MODIFIED_BY="[Empty name]">
<P>Safety, pharmacokinetics</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-01-11 22:56:02 -0500" MODIFIED_BY="[Empty name]">
<P>Abstract only, authors were contacted and advised that the report was under consideration for publication, no further details were provided</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2008-01-11 22:53:58 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weisman-2004">
<CHAR_METHODS MODIFIED="2008-01-11 22:52:20 -0500" MODIFIED_BY="[Empty name]">
<P>Phase 1/2 double blind placebo controlled dose escalation study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-01-11 22:52:40 -0500" MODIFIED_BY="[Empty name]">
<P>Very Low Birth Weight neonates</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-01-11 22:52:48 -0500" MODIFIED_BY="[Empty name]">
<P>Pagibaximab</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-01-11 22:53:17 -0500" MODIFIED_BY="[Empty name]">
<P>Safety, efficacy, immunogenicity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-01-11 22:53:58 -0500" MODIFIED_BY="[Empty name]">
<P>Abstract only, authors were contacted and advised that the report was under consideration for publication, no further details were provided</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-05-19 08:37:10 -0400" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-01-11 11:13:44 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 10:50:12 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benjamin-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 10:59:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bloom-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 11:13:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeJonge-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-01-11 11:13:45 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 10:50:14 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benjamin-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 10:59:17 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bloom-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 11:13:45 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeJonge-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-01-11 11:13:47 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-01-11 10:50:16 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benjamin-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-01-11 10:59:19 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bloom-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-01-11 11:13:47 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeJonge-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-05-19 08:37:10 -0400" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-05-19 08:36:18 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Benjamin-2006">
<DESCRIPTION>
<P>Data for only 28 days after second infusion provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-05-19 08:36:47 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bloom-2005">
<DESCRIPTION>
<P>Data for maximum of 70 days after randomization are provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-05-19 08:37:10 -0400" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-DeJonge-2007">
<DESCRIPTION>
<P>Data for maximum of 70 days after randomization are provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-01-11 11:13:49 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 10:50:21 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benjamin-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 10:59:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bloom-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 11:13:49 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeJonge-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-01-11 11:13:51 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 10:50:23 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benjamin-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 10:59:25 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bloom-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-01-11 11:13:51 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-DeJonge-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-02-10 10:13:31 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-02-10 10:13:31 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Antistaphylococcal immunoglobulin vs. placebo or no treatment</NAME>
<DICH_OUTCOME CHI2="0.22277829275742098" CI_END="1.2085979709395207" CI_START="0.9349604308998034" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0630104795787492" ESTIMABLE="YES" EVENTS_1="388" EVENTS_2="314" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.08228186079568327" LOG_CI_START="-0.029206768812514973" LOG_EFFECT_SIZE="0.02653754599158413" METHOD="MH" MODIFIED="2008-10-21 15:53:08 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8945905569209887" P_Q="0.0" P_Z="0.35079044605814647" Q="0.0" RANDOM="NO" SCALE="3.13695302416163" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1445" TOTAL_2="1249" WEIGHT="200.0" Z="0.9330572016961174">
<NAME>Incidence of staphylococcal infection after intervention</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.03285529105695049" CI_END="1.2157126375408072" CI_START="0.9384859505222697" DF="1.0" EFFECT_SIZE="1.0681428884772017" ESTIMABLE="YES" EVENTS_1="381" EVENTS_2="306" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.08483093128632103" LOG_CI_START="-0.027572224541114732" LOG_EFFECT_SIZE="0.028629353372603132" MODIFIED="2008-09-12 11:14:21 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8561633255251824" P_Z="0.31807814956417946" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.9984150551274174">
<NAME>INH A-21 vs. placebo</NAME>
<DICH_DATA CI_END="1.4189834518698112" CI_START="0.7633466057899334" EFFECT_SIZE="1.0407575133799918" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="42" LOG_CI_END="0.15197733076153846" LOG_CI_START="-0.11727822115110476" LOG_EFFECT_SIZE="0.01734955480521686" MODIFIED="2008-09-12 11:14:21 -0400" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.15816204402996434" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.02501523217173638" WEIGHT="17.903719706370055"/>
<DICH_DATA CI_END="1.2385092126577666" CI_START="0.9315419972859378" EFFECT_SIZE="1.0741151454179623" ESTIMABLE="YES" EVENTS_1="285" EVENTS_2="264" LOG_CI_END="0.09289924143582502" LOG_CI_START="-0.030797560758734632" LOG_EFFECT_SIZE="0.031050840338545212" MODIFIED="2008-01-11 17:48:38 -0500" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.07266011391813039" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.005279492154595685" WEIGHT="82.09628029362995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2795223648533134" CI_START="0.3230769047545679" DF="0.0" EFFECT_SIZE="0.8581730769230769" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.35784385750956904" LOG_CI_START="-0.4906940865386681" LOG_EFFECT_SIZE="-0.06642511451454958" MODIFIED="2008-09-12 11:14:37 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7589505552297459" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.3068591876901735">
<NAME>Altastaph vs. placebo</NAME>
<DICH_DATA CI_END="2.2795223648533134" CI_START="0.3230769047545679" EFFECT_SIZE="0.8581730769230769" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.35784385750956904" LOG_CI_START="-0.4906940865386681" LOG_EFFECT_SIZE="-0.06642511451454958" MODIFIED="2008-09-12 11:14:37 -0400" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.4984353886644996" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.24843783667313077" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7356074726548836" CI_END="1.0552056794305507" CI_START="0.7308889833319225" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8782016888192972" ESTIMABLE="YES" EVENTS_1="196" EVENTS_2="201" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.02333712004656386" LOG_CI_START="-0.1361485841746027" LOG_EFFECT_SIZE="-0.05640573206401945" METHOD="MH" MODIFIED="2008-10-21 15:53:27 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6922531635418163" P_Q="0.0" P_Z="0.1656335484181608" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1445" TOTAL_2="1249" WEIGHT="200.0" Z="1.38637132283386">
<NAME>Incidence of other bacterial infections after intervention</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6861695103240824" CI_END="1.0593302703573522" CI_START="0.7184919510425647" DF="1.0" EFFECT_SIZE="0.8724220725930204" ESTIMABLE="YES" EVENTS_1="177" EVENTS_2="181" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.02503138242279023" LOG_CI_START="-0.1435780927174787" LOG_EFFECT_SIZE="-0.05927335514734428" MODIFIED="2008-09-12 11:35:12 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4074707156673508" P_Z="0.16819701490963435" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="1.37802031866833">
<NAME>INH A-21 vs. placebo</NAME>
<DICH_DATA CI_END="1.9366236245572956" CI_START="0.6166411207545432" EFFECT_SIZE="1.0927953890489914" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="15" LOG_CI_END="0.2870452254374585" LOG_CI_START="-0.20996751768714855" LOG_EFFECT_SIZE="0.03853885387515495" MODIFIED="2008-09-12 11:18:20 -0400" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.29194774556415115" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.08523348613999035" WEIGHT="11.021544544183206"/>
<DICH_DATA CI_END="1.0389558444783966" CI_START="0.6874557885020413" EFFECT_SIZE="0.8451249666674747" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="166" LOG_CI_END="0.016597090476453823" LOG_CI_START="-0.162755226846072" LOG_EFFECT_SIZE="-0.07307906818480911" MODIFIED="2008-09-12 11:35:12 -0400" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.10535243900354081" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.011099136403994788" WEIGHT="88.9784554558168"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6399575644825988" CI_START="0.5293565182006711" DF="0.0" EFFECT_SIZE="0.9317307692307693" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.21483261039557416" LOG_CI_START="-0.27625173489160415" LOG_EFFECT_SIZE="-0.030709562248015018" MODIFIED="2008-01-16 12:46:40 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.806356143269966" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.24512952434638247">
<NAME>Altastaph vs. placebo</NAME>
<DICH_DATA CI_END="1.6399575644825988" CI_START="0.5293565182006711" EFFECT_SIZE="0.9317307692307693" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.21483261039557416" LOG_CI_START="-0.27625173489160415" LOG_EFFECT_SIZE="-0.030709562248015018" MODIFIED="2008-01-16 12:46:40 -0500" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.2884653753284029" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.08321227276335635" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.06379988416338295" CI_END="1.0823939914559413" CI_START="0.9108405038150802" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9929190744990979" ESTIMABLE="YES" EVENTS_1="625" EVENTS_2="547" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.034385372757367944" LOG_CI_START="-0.04055766515366126" LOG_EFFECT_SIZE="-0.0030861461981466685" METHOD="MH" MODIFIED="2008-10-21 15:53:36 -0400" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9686034939480315" P_Q="0.0" P_Z="0.8717608751160836" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1445" TOTAL_2="1249" WEIGHT="200.0" Z="0.16142220993426018">
<NAME>Incidence of any infection after intervention</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.013800882213900103" CI_END="1.0857888908656004" CI_START="0.9121330656187409" DF="1.0" EFFECT_SIZE="0.9951803603568614" ESTIMABLE="YES" EVENTS_1="605" EVENTS_2="526" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.03574539390425323" LOG_CI_START="-0.03994180043424656" LOG_EFFECT_SIZE="-0.002098203264996662" MODIFIED="2008-09-12 11:36:29 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9064819477802449" P_Z="0.9134655133173961" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.10866839146515839">
<NAME>INH A-21 vs. placebo</NAME>
<DICH_DATA CI_END="1.257189908385913" CI_START="0.8069974800516903" EFFECT_SIZE="1.0072482752598027" ESTIMABLE="YES" EVENTS_1="146" EVENTS_2="66" LOG_CI_END="0.09940088622567143" LOG_CI_START="-0.09312782141343677" LOG_EFFECT_SIZE="0.0031365324061173334" MODIFIED="2008-09-12 11:15:32 -0400" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.11309231589968531" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.012789871915554214" WEIGHT="16.435481929909702"/>
<DICH_DATA CI_END="1.0914401844822499" CI_START="0.9030869832741795" EFFECT_SIZE="0.9928068410462777" ESTIMABLE="YES" EVENTS_1="459" EVENTS_2="460" LOG_CI_END="0.03799993953107866" LOG_CI_START="-0.044270417419972084" LOG_EFFECT_SIZE="-0.003135238944446726" MODIFIED="2008-09-12 11:36:29 -0400" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.04832601491788209" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.0023354037178433627" WEIGHT="83.5645180700903"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6158810107053294" CI_START="0.539940232852684" DF="0.0" EFFECT_SIZE="0.9340659340659341" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.20840937729457465" LOG_CI_START="-0.26765431050817634" LOG_EFFECT_SIZE="-0.029622466606800863" MODIFIED="2008-01-16 12:55:01 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.8072985049805628" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.00000000000001" Z="0.24391260736788598">
<NAME>Altastaph vs. placebo</NAME>
<DICH_DATA CI_END="1.6158810107053294" CI_START="0.539940232852684" EFFECT_SIZE="0.9340659340659341" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.20840937729457465" LOG_CI_START="-0.26765431050817634" LOG_EFFECT_SIZE="-0.029622466606800863" MODIFIED="2008-01-16 12:55:01 -0500" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.27964216676859655" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.07819974143503555" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="22.503238662864334" CI_START="0.3316749702725711" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.7319884726224783" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.352245026208777" LOG_CI_START="-0.47928730111439205" LOG_EFFECT_SIZE="0.43647886254719254" METHOD="MH" MODIFIED="2008-10-21 15:53:48 -0400" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.35021533303347185" Q="0.0" RANDOM="NO" SCALE="24.663543111845687" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="347" TOTAL_2="158" WEIGHT="100.0" Z="0.9341717182309481">
<NAME>Infection related mortality prior to discharge</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="22.503238662864334" CI_START="0.3316749702725711" DF="0.0" EFFECT_SIZE="2.7319884726224783" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="1.352245026208777" LOG_CI_START="-0.47928730111439205" LOG_EFFECT_SIZE="0.43647886254719254" MODIFIED="2008-01-17 10:31:30 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.35021533303347185" STUDIES="1" TAU2="0.0" TOTAL_1="347" TOTAL_2="158" WEIGHT="100.0" Z="0.9341717182309481">
<NAME>INH A-21 vs. placebo</NAME>
<DICH_DATA CI_END="22.503238662864334" CI_START="0.3316749702725711" EFFECT_SIZE="2.7319884726224783" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.352245026208777" LOG_CI_START="-0.47928730111439205" LOG_EFFECT_SIZE="0.43647886254719254" MODIFIED="2008-01-16 12:58:44 -0500" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="1.075851155300868" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="1.1574557083622126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5716712114882825" CI_END="1.0973948549875696" CI_START="0.6077132878285698" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8166403341561403" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.04036291972396991" LOG_CI_START="-0.21630126757314858" LOG_EFFECT_SIZE="-0.08796917392458932" METHOD="MH" MODIFIED="2008-10-21 15:53:57 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.7513861534558557" P_Q="0.0" P_Z="0.17910446582160278" Q="0.0" RANDOM="NO" SCALE="5.805923162305186" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1445" TOTAL_2="1249" WEIGHT="200.0" Z="1.343517492312577">
<NAME>All cause mortality prior to discharge</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.16141583095390447" CI_END="1.0817833191582875" CI_START="0.5913125347991081" DF="1.0" EFFECT_SIZE="0.7997949965802984" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="84" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.03414028043996832" LOG_CI_START="-0.22818291461431478" LOG_EFFECT_SIZE="-0.09702131708717322" MODIFIED="2008-01-16 13:02:29 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6878565426400771" P_Z="0.1471138675382576" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="1.4498015486899676">
<NAME>INH A-21 vs. placebo</NAME>
<DICH_DATA CI_END="1.831821239748953" CI_START="0.4527225481386063" EFFECT_SIZE="0.9106628242074928" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.2628830903042564" LOG_CI_START="-0.34416787464919624" LOG_EFFECT_SIZE="-0.040642392172469906" MODIFIED="2008-01-16 13:02:20 -0500" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.3565847417643978" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.12715267805918226" WEIGHT="17.119680918616528"/>
<DICH_DATA CI_END="1.0861213818842745" CI_START="0.5557064556288583" EFFECT_SIZE="0.7768942421653207" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="73" LOG_CI_END="0.03587836350031098" LOG_CI_START="-0.25515455799650777" LOG_EFFECT_SIZE="-0.10963809724809842" MODIFIED="2008-01-16 13:02:29 -0500" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.17095417872342705" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.02922533122300144" WEIGHT="82.88031908138348"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.697818848746117" CI_START="0.3001252263353293" DF="0.0" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.7557086375604313" LOG_CI_START="-0.5226974994175568" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2008-01-16 13:02:01 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7209147025068596" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.35723658198035113">
<NAME>Altastaph vs. placebo</NAME>
<DICH_DATA CI_END="5.697818848746117" CI_START="0.3001252263353293" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7557086375604313" LOG_CI_START="-0.5226974994175568" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2008-01-16 13:02:01 -0500" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.7509420930733083" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.5639140271493213" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5170398229758499" CI_END="1.0432279944734217" CI_START="0.9483644581461008" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9946659498050741" ESTIMABLE="YES" EVENTS_1="972" EVENTS_2="848" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.018379232607749794" LOG_CI_START="-0.023024730442754958" LOG_EFFECT_SIZE="-0.0023227489175025734" METHOD="MH" MODIFIED="2009-02-10 10:13:31 -0500" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.47210721289587276" P_Q="0.0" P_Z="0.825943826521132" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.21990668950608805">
<NAME>Chronic lung disease</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5170398229758499" CI_END="1.0432279944734217" CI_START="0.9483644581461008" DF="1.0" EFFECT_SIZE="0.9946659498050741" ESTIMABLE="YES" EVENTS_1="972" EVENTS_2="848" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.018379232607749794" LOG_CI_START="-0.023024730442754958" LOG_EFFECT_SIZE="-0.0023227489175025734" MODIFIED="2008-01-16 13:04:29 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.47210721289587276" P_Z="0.825943826521132" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.21990668950608805">
<NAME>Chronic lung disease at 28 days (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.086279490121383" CI_START="0.8357627522642143" EFFECT_SIZE="0.9528231401430248" ESTIMABLE="YES" EVENTS_1="226" EVENTS_2="108" LOG_CI_END="0.035941579765711856" LOG_CI_START="-0.07791698811771161" LOG_EFFECT_SIZE="-0.020987704175999898" MODIFIED="2008-01-11 18:10:58 -0500" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.06688108638372373" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.004473079715867114" WEIGHT="16.67103137233785"/>
<DICH_DATA CI_END="1.0554230167845204" CI_START="0.9532514373567113" EFFECT_SIZE="1.003037141769536" ESTIMABLE="YES" EVENTS_1="746" EVENTS_2="740" LOG_CI_END="0.023426561087561176" LOG_CI_START="-0.020792531204443788" LOG_EFFECT_SIZE="0.0013170149415586722" MODIFIED="2008-01-11 18:11:19 -0500" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.02597451370036074" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="6.746753619702277E-4" WEIGHT="83.32896862766215"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.507832935400516" CI_END="1.1121878620070833" CI_START="0.974065150065753" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0408378532255822" ESTIMABLE="YES" EVENTS_1="1288" EVENTS_2="1048" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.04617815104288624" LOG_CI_START="-0.01141199448914365" LOG_EFFECT_SIZE="0.017383078276871293" METHOD="MH" MODIFIED="2008-10-21 15:54:13 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.7429273145358998" P_Q="0.0" P_Z="0.23673160286703643" Q="0.0" RANDOM="NO" SCALE="2.2059352603127333" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4127" TOTAL_2="3543" WEIGHT="400.0" Z="1.1831957376860431">
<NAME>Patent ductus arteriosus</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9613928556314786" CI_END="1.1885476478610677" CI_START="0.9406255737823213" DF="1.0" EFFECT_SIZE="1.0573449357881963" ESTIMABLE="YES" EVENTS_1="449" EVENTS_2="357" I2="49.01582326412392" ID="CMP-001.07.01" LOG_CI_END="0.07501659690840962" LOG_CI_START="-0.026583217806014848" LOG_EFFECT_SIZE="0.02421668955119736" MODIFIED="2008-01-16 13:05:03 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16136473644075078" P_Z="0.3501340916922303" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.9343292500787543">
<NAME>PDA treated medically (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.6389590640675578" CI_START="0.9602017537253988" EFFECT_SIZE="1.2544845027348115" ESTIMABLE="YES" EVENTS_1="135" EVENTS_2="49" LOG_CI_END="0.21456810642492788" LOG_CI_START="-0.017637505164845184" LOG_EFFECT_SIZE="0.09846530063004136" MODIFIED="2008-01-11 18:18:56 -0500" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="0.13639872568414793" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.01860461236825944" WEIGHT="17.903719706370058"/>
<DICH_DATA CI_END="1.1554280060109825" CI_START="0.8905017709825457" EFFECT_SIZE="1.0143523478533538" ESTIMABLE="YES" EVENTS_1="314" EVENTS_2="308" LOG_CI_END="0.06274289004339201" LOG_CI_START="-0.050365212498118525" LOG_EFFECT_SIZE="0.0061888387726367336" MODIFIED="2008-01-11 18:19:36 -0500" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.0664402593270207" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.004414308059441761" WEIGHT="82.09628029362995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13479150154065306" CI_END="1.22494069821804" CI_START="0.8269288514859137" DF="1.0" EFFECT_SIZE="1.0064486100719683" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="161" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.08811506416171568" LOG_CI_START="-0.08253185530393384" LOG_EFFECT_SIZE="0.0027916044288908955" MODIFIED="2008-01-16 13:05:15 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.713514971070907" P_Z="0.9488699744621196" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.00000000000001" Z="0.06412590578067882">
<NAME>PDA treated surgically (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.4767490889909793" CI_START="0.5862576955431971" EFFECT_SIZE="0.930459842125047" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="23" LOG_CI_END="0.1693067116128975" LOG_CI_START="-0.23191144344955064" LOG_EFFECT_SIZE="-0.031302365918326525" MODIFIED="2008-01-11 18:20:07 -0500" MODIFIED_BY="[Empty name]" ORDER="21" O_E="0.0" SE="0.23567753034558042" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.05554389830979198" WEIGHT="18.5977214108085"/>
<DICH_DATA CI_END="1.272074193118557" CI_START="0.8239974890720805" EFFECT_SIZE="1.0238095238095237" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="138" LOG_CI_END="0.10451244206892789" LOG_CI_START="-0.0840741117055558" LOG_EFFECT_SIZE="0.010219165181686028" MODIFIED="2008-01-11 18:20:49 -0500" MODIFIED_BY="[Empty name]" ORDER="22" O_E="0.0" SE="0.11077667520562846" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.0122714717696133" WEIGHT="81.40227858919151"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2110387424749016" CI_END="1.1357246655146052" CI_START="0.9551004544857311" DF="1.0" EFFECT_SIZE="1.0415042698921855" ESTIMABLE="YES" EVENTS_1="638" EVENTS_2="518" I2="17.42625855582612" ID="CMP-001.07.03" LOG_CI_END="0.055273057835397876" LOG_CI_START="-0.019950948275428374" LOG_EFFECT_SIZE="0.01766105477998475" MODIFIED="2008-01-16 13:06:22 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.27112656783520594" P_Z="0.3574062290169978" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="99.99999999999999" Z="0.9203187409817383">
<NAME>PDA treated medically or surgically (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.4025469580222392" CI_START="0.9445296528656562" EFFECT_SIZE="1.1509766250400255" ESTIMABLE="YES" EVENTS_1="182" EVENTS_2="72" LOG_CI_END="0.1469174105831304" LOG_CI_START="-0.024784403148419967" LOG_EFFECT_SIZE="0.0610665037173552" MODIFIED="2008-01-11 18:22:49 -0500" MODIFIED_BY="[Empty name]" ORDER="24" O_E="0.0" SE="0.10085849532359828" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.010172436078940295" WEIGHT="18.119716617278034"/>
<DICH_DATA CI_END="1.120201007980992" CI_START="0.9238124762720884" EFFECT_SIZE="1.017278559247864" ESTIMABLE="YES" EVENTS_1="456" EVENTS_2="446" LOG_CI_END="0.04929595912042572" LOG_CI_START="-0.03441617681610726" LOG_EFFECT_SIZE="0.0074398911521592346" MODIFIED="2008-01-11 18:23:13 -0500" MODIFIED_BY="[Empty name]" ORDER="25" O_E="0.0" SE="0.049172923030875414" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.002417976359400398" WEIGHT="81.88028338272196"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.080639794812168" CI_START="0.4623137010173863" DF="0.0" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.31819690065090955" LOG_CI_START="-0.33506323572463514" LOG_EFFECT_SIZE="-0.008433167536862813" MODIFIED="2008-01-16 13:07:28 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.9596412786485113" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.05060374490183644">
<NAME>PDA treated medically or surgically (Altastaph vs. placebo)</NAME>
<DICH_DATA CI_END="2.080639794812168" CI_START="0.4623137010173863" EFFECT_SIZE="0.9807692307692307" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.31819690065090955" LOG_CI_START="-0.33506323572463514" LOG_EFFECT_SIZE="-0.008433167536862813" MODIFIED="2008-01-16 13:07:28 -0500" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.3837282377968223" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.1472473604826546" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.674663075794352" CI_END="1.2100245526072289" CI_START="0.7218076833487987" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9345614046773976" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="107" I2="11.889041988627865" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.082794182674841" LOG_CI_START="-0.1415784993640343" LOG_EFFECT_SIZE="-0.029392158344596655" METHOD="MH" MODIFIED="2008-10-21 15:54:22 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.339173354709968" P_Q="0.0" P_Z="0.6076023255004432" Q="0.0" RANDOM="NO" SCALE="10.367563115401676" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="3133" TOTAL_2="2554" WEIGHT="400.0" Z="0.5134989808904336">
<NAME>Necrotising enterocolitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5262340713291465" CI_START="0.2568262888446599" DF="0.0" EFFECT_SIZE="0.6260806916426513" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="0.18362114442553226" LOG_CI_START="-0.5903605237658714" LOG_EFFECT_SIZE="-0.2033696896701696" MODIFIED="2008-01-17 10:13:57 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.30301401315266585" STUDIES="1" TAU2="0.0" TOTAL_1="347" TOTAL_2="158" WEIGHT="100.0" Z="1.0299914938089925">
<NAME>NEC stage 1 (INH A21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.5262340713291465" CI_START="0.2568262888446599" EFFECT_SIZE="0.6260806916426513" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.18362114442553226" LOG_CI_START="-0.5903605237658714" LOG_EFFECT_SIZE="-0.2033696896701696" MODIFIED="2008-01-11 18:30:12 -0500" MODIFIED_BY="[Empty name]" ORDER="26" O_E="0.0" SE="0.45464066316667806" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.20669813260463682" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.884034000567129" CI_END="1.3813318437212712" CI_START="0.7254503660764178" DF="1.0" EFFECT_SIZE="1.0010433016111786" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="70" I2="74.2535724493147" ID="CMP-001.08.02" LOG_CI_END="0.14029802367969013" LOG_CI_START="-0.1393922958058612" LOG_EFFECT_SIZE="4.5286393691442415E-4" MODIFIED="2008-01-17 10:14:18 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04874735359879234" P_Z="0.9949358619632805" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.006346998407967018">
<NAME>NEC stage 2 (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="10.066497870134873" CI_START="0.9153649948486179" EFFECT_SIZE="3.0355427473583094" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="3" LOG_CI_END="1.0028784059841505" LOG_CI_START="-0.03840569976841516" LOG_EFFECT_SIZE="0.48223635310786767" MODIFIED="2008-01-11 18:30:44 -0500" MODIFIED_BY="[Empty name]" ORDER="27" O_E="0.0" SE="0.6116554381585103" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.37412237502887924" WEIGHT="5.782961833039638"/>
<DICH_DATA CI_END="1.2293304867894663" CI_START="0.6244613739168108" EFFECT_SIZE="0.8761674524760503" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="67" LOG_CI_END="0.08966865204393157" LOG_CI_START="-0.20449441976156385" LOG_EFFECT_SIZE="-0.057412883858816155" MODIFIED="2008-01-11 18:31:48 -0500" MODIFIED_BY="[Empty name]" ORDER="28" O_E="0.0" SE="0.17279284450923763" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.02985736711359357" WEIGHT="94.21703816696036"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.31765458899383126" CI_END="1.403844542124117" CI_START="0.4569922431552459" DF="1.0" EFFECT_SIZE="0.8009657085959107" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" I2="0.0" ID="CMP-001.08.03" LOG_CI_END="0.14731901788231133" LOG_CI_START="-0.34009117144757567" LOG_EFFECT_SIZE="-0.09638607678263218" MODIFIED="2008-01-17 10:14:43 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5730206943069486" P_Z="0.43823834445662824" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.7751714807800699">
<NAME>NEC stage 3 (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="2.345780378818038" CI_START="0.40583949890790705" EFFECT_SIZE="0.9757101687937423" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.37028734932587287" LOG_CI_START="-0.3916456869159263" LOG_EFFECT_SIZE="-0.010679168795026683" MODIFIED="2008-01-11 18:32:14 -0500" MODIFIED_BY="[Empty name]" ORDER="29" O_E="0.0" SE="0.44756323711779034" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.2003128512193554" WEIGHT="36.0796698355837"/>
<DICH_DATA CI_END="1.4628222422339103" CI_START="0.3372041482014948" EFFECT_SIZE="0.7023316368801041" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.16519155517025497" LOG_CI_START="-0.47210709143182106" LOG_EFFECT_SIZE="-0.15345776813078302" MODIFIED="2008-01-11 18:32:29 -0500" MODIFIED_BY="[Empty name]" ORDER="30" O_E="0.0" SE="0.3743523796932382" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.14013970418199037" WEIGHT="63.9203301644163"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.185879924628562" CI_START="0.4504047585296389" DF="0.0" EFFECT_SIZE="1.373076923076923" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-001.08.04" LOG_CI_END="0.6217867660907767" LOG_CI_START="-0.34639702980802617" LOG_EFFECT_SIZE="0.13769486814137524" MODIFIED="2008-01-17 11:28:55 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5771918593060236" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.5574912192422098">
<NAME>NEC any stage or gastrointestinal perforation (not pre-specifed outcome of review)</NAME>
<DICH_DATA CI_END="4.185879924628562" CI_START="0.4504047585296389" EFFECT_SIZE="1.373076923076923" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6217867660907767" LOG_CI_START="-0.34639702980802617" LOG_EFFECT_SIZE="0.13769486814137524" MODIFIED="2008-01-17 11:28:55 -0500" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.5687159542980403" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.32343783667313075" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0608083445134464" CI_END="1.0354514575579816" CI_START="0.8425242770770004" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9340198021066602" ESTIMABLE="YES" EVENTS_1="563" EVENTS_2="521" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.015129743781031784" LOG_CI_START="-0.07441757621487405" LOG_EFFECT_SIZE="-0.029643916216921144" METHOD="MH" MODIFIED="2008-10-21 15:54:29 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.9004395008754827" P_Q="0.0" P_Z="0.19440403703376255" Q="0.0" RANDOM="NO" SCALE="2.9257850103683607" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2786" TOTAL_2="2396" WEIGHT="300.0" Z="1.297660458147597">
<NAME>Intraventricular hemorrhage</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4948439358511668" CI_END="1.0378017851853936" CI_START="0.8260740596526074" DF="1.0" EFFECT_SIZE="0.9259055749928398" ESTIMABLE="YES" EVENTS_1="422" EVENTS_2="394" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="0.016114413415661936" LOG_CI_START="-0.08298101532291434" LOG_EFFECT_SIZE="-0.033433300953626205" MODIFIED="2008-01-17 10:18:01 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48177450493673324" P_Z="0.18599355937365283" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="1.3225244915437147">
<NAME>Any grade of IVH (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.356716342998085" CI_START="0.7626917524284007" EFFECT_SIZE="1.0172297504445398" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="47" LOG_CI_END="0.13248905654116538" LOG_CI_START="-0.11765094994562639" LOG_EFFECT_SIZE="0.007419053297769495" MODIFIED="2008-01-11 18:34:53 -0500" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="0.14693347802334322" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.021589446964036287" WEIGHT="15.659533142575832"/>
<DICH_DATA CI_END="1.0292096705007374" CI_START="0.8027411587935377" EFFECT_SIZE="0.9089493734742751" ESTIMABLE="YES" EVENTS_1="317" EVENTS_2="347" LOG_CI_END="0.012503858208126765" LOG_CI_START="-0.09542446895463907" LOG_EFFECT_SIZE="-0.04146030537325612" MODIFIED="2008-01-11 18:34:40 -0500" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.06339763362924446" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.004019259949787907" WEIGHT="84.34046685742418"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6422439241141085" CI_START="0.34658462793785366" DF="0.0" EFFECT_SIZE="0.7544378698224852" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="0.21543766376336315" LOG_CI_START="-0.4601907034507623" LOG_EFFECT_SIZE="-0.12237651984369959" MODIFIED="2008-01-17 10:18:19 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.47769404311251606" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.7100162843546982">
<NAME>Any grade of IVH (Altastaph vs. placebo)</NAME>
<DICH_DATA CI_END="1.6422439241141085" CI_START="0.34658462793785366" EFFECT_SIZE="0.7544378698224852" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.21543766376336315" LOG_CI_START="-0.4601907034507623" LOG_EFFECT_SIZE="-0.12237651984369959" MODIFIED="2008-01-17 10:17:53 -0500" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.39686744731593304" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.15750377073906488" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.08887474088267786" CI_END="1.2501284663427479" CI_START="0.7707639186314594" DF="1.0" EFFECT_SIZE="0.9816078216431819" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="114" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="0.09695464449365075" LOG_CI_START="-0.11307862394137098" LOG_EFFECT_SIZE="-0.00806198972386011" MODIFIED="2008-01-17 10:18:19 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.765612608303765" P_Z="0.8803986515129776" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.15046387289246294">
<NAME>Grade 3 or grade 4 IVH (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.8878395077092176" CI_START="0.5979208864645819" EFFECT_SIZE="1.0624399615754083" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="15" LOG_CI_END="0.2759650705346357" LOG_CI_START="-0.22335627561834898" LOG_EFFECT_SIZE="0.026304397458143322" MODIFIED="2008-01-11 18:36:01 -0500" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.29330383041078945" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.08602713693364114" WEIGHT="17.197782711417325"/>
<DICH_DATA CI_END="1.2595734391155018" CI_START="0.7390407698121633" EFFECT_SIZE="0.9648192183403451" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="99" LOG_CI_END="0.10022349400388844" LOG_CI_START="-0.1313316027201193" LOG_EFFECT_SIZE="-0.0155540543581154" MODIFIED="2008-01-11 18:36:20 -0500" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.13601661003189686" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.018500518204569102" WEIGHT="82.80221728858268"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.6644890434540214" CI_END="1.6544181319839981" CI_START="0.7436654807472483" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1092040639480385" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="44" I2="62.46935214626803" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.21864528119228435" LOG_CI_START="-0.12862237700239135" LOG_EFFECT_SIZE="0.04501145209494648" METHOD="MH" MODIFIED="2008-10-21 15:54:36 -0400" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.1026108309371252" P_Q="0.0" P_Z="0.6113934092799839" Q="0.0" RANDOM="NO" SCALE="9.627458118949606" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.5080854661592997">
<NAME>Periventricular leukomalacia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6644890434540214" CI_END="1.6544181319839981" CI_START="0.7436654807472483" DF="1.0" EFFECT_SIZE="1.1092040639480385" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="44" I2="62.46935214626803" ID="CMP-001.10.01" LOG_CI_END="0.21864528119228435" LOG_CI_START="-0.12862237700239135" LOG_EFFECT_SIZE="0.04501145209494648" MODIFIED="2008-01-17 10:33:16 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1026108309371252" P_Z="0.6113934092799839" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.5080854661592997">
<NAME>INH A-21 vs. placebo</NAME>
<DICH_DATA CI_END="9.140549921046956" CI_START="0.8165549205476255" EFFECT_SIZE="2.7319884726224783" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" LOG_CI_END="0.9609723248904792" LOG_CI_START="-0.08801459979609419" LOG_EFFECT_SIZE="0.43647886254719254" MODIFIED="2008-01-11 18:38:35 -0500" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.6161801121299151" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.3796779305844348" WEIGHT="9.115903490353068"/>
<DICH_DATA CI_END="1.454142547467283" CI_START="0.6159909521214537" EFFECT_SIZE="0.9464347057957501" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="41" LOG_CI_END="0.16260698186276903" LOG_CI_START="-0.21042566684950947" LOG_EFFECT_SIZE="-0.023909342493370213" MODIFIED="2008-01-11 18:38:50 -0500" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.21912122439498416" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.048014110980357" WEIGHT="90.88409650964694"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.061124581642764" CI_END="1.0677472880408825" CI_START="0.8912384790867786" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.975508825712299" ESTIMABLE="YES" EVENTS_1="636" EVENTS_2="556" I2="40.72463636083335" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.028468477040677998" LOG_CI_START="-0.050006071166869594" LOG_EFFECT_SIZE="-0.01076879706309579" METHOD="MH" MODIFIED="2008-10-21 15:54:42 -0400" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.16737582928804173" P_Q="0.0" P_Z="0.5906333397216925" Q="0.0" RANDOM="NO" SCALE="2.9921438761830172" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="2682" TOTAL_2="2294" WEIGHT="200.0" Z="0.537918468664939">
<NAME>Retinopathy of prematurity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.6220845548416207" CI_END="1.100574519552891" CI_START="0.9133259496413508" DF="1.0" EFFECT_SIZE="1.0025882845025258" ESTIMABLE="YES" EVENTS_1="561" EVENTS_2="479" I2="61.86240454551619" ID="CMP-001.11.01" LOG_CI_END="0.04161945382705958" LOG_CI_START="-0.0393742028952374" LOG_EFFECT_SIZE="0.0011226254659110672" MODIFIED="2008-01-17 10:20:53 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10538596333798433" P_Z="0.956670029215364" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="99.99999999999999" Z="0.05433278531570392">
<NAME>Any stgae of ROP (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.0571541011800396" CI_START="0.6907363946720763" EFFECT_SIZE="0.8545260747700446" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="73" LOG_CI_END="0.02413829895744" LOG_CI_START="-0.16068766055844044" LOG_EFFECT_SIZE="-0.06827468080050023" MODIFIED="2008-01-11 18:39:58 -0500" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.10856768352288314" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.01178694190552491" WEIGHT="19.773702751535712"/>
<DICH_DATA CI_END="1.1527266849726365" CI_START="0.9366408901292647" EFFECT_SIZE="1.0390817813283644" ESTIMABLE="YES" EVENTS_1="424" EVENTS_2="406" LOG_CI_END="0.06172634694858796" LOG_CI_START="-0.028426886517778697" LOG_EFFECT_SIZE="0.016649730215404654" MODIFIED="2008-01-11 18:40:15 -0500" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.05295645560384672" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.0028043861901221887" WEIGHT="80.22629724846428"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6855796013030555" CI_END="1.1024500984231174" CI_START="0.5944293909121892" DF="1.0" EFFECT_SIZE="0.8095237739045942" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="77" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="0.04235894057075692" LOG_CI_START="-0.22589972550014276" LOG_EFFECT_SIZE="-0.09177039246469294" MODIFIED="2008-01-17 10:21:48 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.40767238165458763" P_Z="0.17992232016732598" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="1.3409942479201484">
<NAME>Stage 3 or 4 ROP (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.2033020081734487" CI_START="0.33770434948386907" EFFECT_SIZE="0.6374639769452449" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.08037464148974081" LOG_CI_START="-0.471463345806167" LOG_EFFECT_SIZE="-0.1955443521582131" MODIFIED="2008-01-11 18:41:18 -0500" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="0.3241523653797087" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.10507475598126019" WEIGHT="24.904934181118918"/>
<DICH_DATA CI_END="1.234730115575486" CI_START="0.6082077001095599" EFFECT_SIZE="0.8665866164730317" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="62" LOG_CI_END="0.09157204089523581" LOG_CI_START="-0.21594808584607433" LOG_EFFECT_SIZE="-0.0621880224754193" MODIFIED="2008-01-11 18:41:30 -0500" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="0.1806388446970235" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.03263039221347537" WEIGHT="75.09506581888108"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.029141030653217978" CI_END="1.188345537011763" CI_START="-1.1451739988452982" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.02158576908323229" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2008-10-21 15:54:50 -0400" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8644538428298707" P_Q="1.0" P_Z="0.9710746200734328" Q="0.0" RANDOM="NO" SCALE="6.290128827303924" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1341" TOTAL_2="1147" UNITS="" WEIGHT="100.0" Z="0.03626053206895028">
<NAME>Duration of antibiotic use prior to discharge</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.029141030653217978" CI_END="1.188345537011763" CI_START="-1.1451739988452982" DF="1.0" EFFECT_SIZE="0.02158576908323229" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" MODIFIED="2008-01-17 10:35:22 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8644538428298707" P_Z="0.9710746200734328" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.03626053206895028">
<NAME>INH A-21 vs. placebo</NAME>
<CONT_DATA CI_END="6.115425685551177" CI_START="-5.115425685551177" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="26.4" MEAN_2="25.9" MODIFIED="2008-01-11 22:20:40 -0500" MODIFIED_BY="[Empty name]" ORDER="52" SD_1="30.4" SD_2="29.6" SE="2.8650657511285607" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" WEIGHT="4.317153816646458"/>
<CONT_DATA CI_END="1.1927911350489067" CI_START="-1.1927911350489067" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="17.4" MODIFIED="2008-01-11 22:21:21 -0500" MODIFIED_BY="[Empty name]" ORDER="53" SD_1="13.5" SD_2="13.6" SE="0.6085780884023844" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" WEIGHT="95.68284618335355"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0913073066695751" CI_END="0.7819891693099122" CI_START="-0.6799736618855906" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.05100775371216078" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2008-09-12 12:30:19 -0400" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.762521735554368" P_Q="1.0" P_Z="0.8912158068201111" Q="0.0" RANDOM="NO" SCALE="2.204716903144654" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="1341" TOTAL_2="1147" UNITS="" WEIGHT="100.0" Z="0.13676593970090517">
<NAME>Duration of Vancomycin use before discharge</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0913073066695751" CI_END="0.7819891693099122" CI_START="-0.6799736618855906" DF="1.0" EFFECT_SIZE="0.05100775371216078" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" MODIFIED="2008-01-17 10:35:58 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.762521735554368" P_Z="0.8912158068201111" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.13676593970090517">
<NAME>INH A-21 vs. placebo</NAME>
<CONT_DATA CI_END="2.072755591158823" CI_START="-1.4727555911588233" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="7.7" MODIFIED="2008-01-11 22:23:11 -0500" MODIFIED_BY="[Empty name]" ORDER="54" SD_1="10.1" SD_2="9.1" SE="0.9044837584476515" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" WEIGHT="17.00258457072027"/>
<CONT_DATA CI_END="0.8023688342348428" CI_START="-0.8023688342348428" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="11.8" MODIFIED="2008-01-11 22:23:36 -0500" MODIFIED_BY="[Empty name]" ORDER="55" SD_1="8.6" SD_2="9.6" SE="0.4093793766435638" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" WEIGHT="82.99741542927973"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-02-04 15:43:59 -0500" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="0.0" Z="0.0">
<NAME>Allergic reactions</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2008-02-04 15:43:59 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="0.0" Z="0.0">
<NAME>INH A-21 vs. placebo</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-11 22:12:50 -0500" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.0" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-01-11 22:12:54 -0500" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.0" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.517877401371198" CI_END="2.2582003892966163" CI_START="0.9387785131068441" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.456004808975978" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.35376247793628013" LOG_CI_START="-0.027436859152185935" LOG_EFFECT_SIZE="0.1631628093920471" METHOD="MH" MODIFIED="2008-01-17 14:08:32 -0500" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.47174859474932784" P_Q="0.0" P_Z="0.0933809178313868" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="1.6778267898748769">
<NAME>Pulmonary edema</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.517877401371198" CI_END="2.2582003892966163" CI_START="0.9387785131068441" DF="1.0" EFFECT_SIZE="1.456004808975978" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="32" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.35376247793628013" LOG_CI_START="-0.027436859152185935" LOG_EFFECT_SIZE="0.1631628093920471" MODIFIED="2008-01-17 10:34:46 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.47174859474932784" P_Z="0.0933809178313868" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="1.6778267898748769">
<NAME>INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="75.91682113061576" CI_START="0.22273207604514586" EFFECT_SIZE="4.112068965517241" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.8803380145623327" LOG_CI_START="-0.6522172349359416" LOG_EFFECT_SIZE="0.6140603898131954" MODIFIED="2008-01-11 22:15:34 -0500" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="1.487635489905955" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="2.2130593508277308" WEIGHT="2.094756715427881"/>
<DICH_DATA CI_END="2.1825113980125694" CI_START="0.8969915768702524" EFFECT_SIZE="1.3991763078470825" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="32" LOG_CI_END="0.3389565204559752" LOG_CI_START="-0.04721163514536756" LOG_EFFECT_SIZE="0.14587244265530377" MODIFIED="2008-01-11 22:15:44 -0500" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.22683708616342824" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.051455063659114564" WEIGHT="97.90524328457212"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.652845941989736" CI_END="1.6234721135071921" CI_START="0.8861619713632731" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1994412234698426" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.21044483311972842" LOG_CI_START="-0.052486891160031364" LOG_EFFECT_SIZE="0.07897897097984853" METHOD="MH" MODIFIED="2008-10-21 15:55:11 -0400" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.43761207646049594" P_Q="0.0" P_Z="0.23901153583306878" Q="0.0" RANDOM="NO" SCALE="10.843354414546562" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1445" TOTAL_2="1249" WEIGHT="200.0" Z="1.177461100067439">
<NAME>Hypertension</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4017713381760013" CI_END="1.6106399048839033" CI_START="0.8423040607914825" DF="1.0" EFFECT_SIZE="1.1647525627173003" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="62" I2="28.661688767212926" ID="CMP-001.16.01" LOG_CI_END="0.20699845488070376" LOG_CI_START="-0.07453110554723474" LOG_EFFECT_SIZE="0.06623367466673448" MODIFIED="2008-01-17 10:23:53 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23642743474033656" P_Z="0.35641561711682235" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.9222165993028694">
<NAME>INH A-21 vs. placebo</NAME>
<DICH_DATA CI_END="2.2310681096582825" CI_START="0.09292710247207403" EFFECT_SIZE="0.4553314121037464" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.34851282855243954" LOG_CI_START="-1.0318576042253418" LOG_EFFECT_SIZE="-0.3416723878364511" MODIFIED="2008-01-11 22:17:58 -0500" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.8108364251575113" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.6574557083622125" WEIGHT="6.515998326164525"/>
<DICH_DATA CI_END="1.6935438503425668" CI_START="0.8705311937628266" EFFECT_SIZE="1.2142004569791631" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="59" LOG_CI_END="0.22879644616237624" LOG_CI_START="-0.0602156621843955" LOG_EFFECT_SIZE="0.08429039198899037" MODIFIED="2008-01-11 22:18:16 -0500" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.16976714307590296" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.028820882868154103" WEIGHT="93.48400167383548"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.448469459976918" CI_START="0.6276099191749087" DF="0.0" EFFECT_SIZE="1.4711538461538463" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-001.16.02" LOG_CI_END="0.5376263841825122" LOG_CI_START="-0.2023102011448752" LOG_EFFECT_SIZE="0.16765809151881847" MODIFIED="2008-01-17 10:23:47 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.3744361197404086" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.8881945496672872">
<NAME>Altastaph vs. placebo</NAME>
<DICH_DATA CI_END="3.448469459976918" CI_START="0.6276099191749087" EFFECT_SIZE="1.4711538461538463" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5376263841825122" LOG_CI_START="-0.2023102011448752" LOG_EFFECT_SIZE="0.16765809151881847" MODIFIED="2008-01-17 10:23:47 -0500" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.4346424129664767" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.18891402714932126" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4386951063321785" CI_END="1.4797767762093286" CI_START="0.9200279224413574" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1668058763534053" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="109" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.17019620717049858" LOG_CI_START="-0.0361989918085936" LOG_EFFECT_SIZE="0.06699860768095248" METHOD="MH" MODIFIED="2008-10-21 15:55:19 -0400" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.48707001410626893" P_Q="0.0" P_Z="0.2032096131796306" Q="0.0" RANDOM="NO" SCALE="3.5804146565855475" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1445" TOTAL_2="1249" WEIGHT="200.0" Z="1.2724603936383012">
<NAME>Hypoglycemia</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2771792279462892" CI_END="1.4722567596686131" CI_START="0.9002950128878251" DF="1.0" EFFECT_SIZE="1.1512885904151233" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="102" I2="21.70245349135492" ID="CMP-001.17.01" LOG_CI_END="0.1679835570009022" LOG_CI_START="-0.04561515558834846" LOG_EFFECT_SIZE="0.061184200706276864" MODIFIED="2008-01-17 10:25:07 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.25842427445858684" P_Z="0.26150451507881367" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="99.99999999999999" Z="1.1228422526850728">
<NAME>INH A-21 vs. placebo</NAME>
<DICH_DATA CI_END="1.5789280377488075" CI_START="0.4021323250922043" EFFECT_SIZE="0.7968299711815562" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.19836233677157064" LOG_CI_START="-0.3956310150718839" LOG_EFFECT_SIZE="-0.09863433915015665" MODIFIED="2008-01-11 22:19:28 -0500" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.3489146351873576" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.12174142264792684" WEIGHT="15.452956695852299"/>
<DICH_DATA CI_END="1.5839653661081972" CI_START="0.9336293253443058" EFFECT_SIZE="1.2160742231164767" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="90" LOG_CI_END="0.19974568137434778" LOG_CI_START="-0.029825515536815207" LOG_EFFECT_SIZE="0.08496008291876628" MODIFIED="2008-01-11 22:19:37 -0500" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.1348512574613694" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.018184861638912534" WEIGHT="84.54704330414769"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.5385476744739317" CI_START="0.5547694453353365" DF="0.0" EFFECT_SIZE="1.401098901098901" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.5488250511837464" LOG_CI_START="-0.25588746628598574" LOG_EFFECT_SIZE="0.14646879244888036" MODIFIED="2008-01-17 10:25:00 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.4755481526036357" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.7134810303722547">
<NAME>Altastaph vs. placebo</NAME>
<DICH_DATA CI_END="3.5385476744739326" CI_START="0.5547694453353365" EFFECT_SIZE="1.401098901098901" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.5488250511837465" LOG_CI_START="-0.25588746628598574" LOG_EFFECT_SIZE="0.14646879244888036" MODIFIED="2008-01-17 10:25:00 -0500" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.4726921161529255" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.2234378366731308" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4879568814468742" CI_END="1.4045049830489948" CI_START="0.7394115381876073" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0190717295207519" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.14752328437550538" LOG_CI_START="-0.1311137767381462" LOG_EFFECT_SIZE="0.008204753818679557" METHOD="MH" MODIFIED="2008-10-21 15:55:29 -0400" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.8287726909394194" P_Q="0.0" P_Z="0.9081072368500451" Q="0.0" RANDOM="NO" SCALE="4.058242655682166" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="1896" TOTAL_2="1509" WEIGHT="400.0" Z="0.11542629628920911">
<NAME>Other adverse effects</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.885995844841755" CI_START="0.24734151174549482" DF="0.0" EFFECT_SIZE="0.6829971181556196" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="0.2755407315803737" LOG_CI_START="-0.6067029891419135" LOG_EFFECT_SIZE="-0.16558112878076986" MODIFIED="2008-01-17 10:28:09 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.46191371448749985" STUDIES="1" TAU2="0.0" TOTAL_1="347" TOTAL_2="158" WEIGHT="100.0" Z="0.7356993114422042">
<NAME>Discontinuation of study medication due to adverse event (INH A21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.885995844841755" CI_START="0.24734151174549482" EFFECT_SIZE="0.6829971181556196" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.2755407315803737" LOG_CI_START="-0.6067029891419135" LOG_EFFECT_SIZE="-0.16558112878076986" MODIFIED="2008-01-11 22:37:49 -0500" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.518234328729122" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.2685668194733237" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7354381870440054" CI_START="0.37081270245571996" DF="0.0" EFFECT_SIZE="1.176923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="0.5723415542245309" LOG_CI_START="-0.43084539720300696" LOG_EFFECT_SIZE="0.07074807851076205" MODIFIED="2008-01-17 10:28:13 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7822052608564918" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.2764463506212615">
<NAME>Discontinuation of study medication due to adverse effects (Altastaph vs. placebo)</NAME>
<DICH_DATA CI_END="3.7354381870440054" CI_START="0.37081270245571996" EFFECT_SIZE="1.176923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5723415542245309" LOG_CI_START="-0.43084539720300696" LOG_EFFECT_SIZE="0.07074807851076205" MODIFIED="2008-01-17 10:27:58 -0500" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.5892769811240336" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.3472473604826546" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7611662472422113" CI_END="1.5124470188233616" CI_START="0.7178808587848882" DF="1.0" EFFECT_SIZE="1.0419965281801848" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="49" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="0.17968017021001692" LOG_CI_START="-0.14394762632273644" LOG_EFFECT_SIZE="0.017866271943640235" MODIFIED="2008-01-17 10:29:26 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.38296383120205824" P_Z="0.8286724888955734" STUDIES="2" TAU2="0.0" TOTAL_1="1341" TOTAL_2="1147" WEIGHT="100.0" Z="0.21640446168528857">
<NAME>Serious adverse events (INH A-21 vs. placebo)</NAME>
<DICH_DATA CI_END="1.885995844841755" CI_START="0.24734151174549482" EFFECT_SIZE="0.6829971181556196" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.2755407315803737" LOG_CI_START="-0.6067029891419135" LOG_EFFECT_SIZE="-0.16558112878076986" MODIFIED="2008-01-11 22:37:40 -0500" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="0.518234328729122" STUDY_ID="STD-Bloom-2005" TOTAL_1="347" TOTAL_2="158" VAR="0.2685668194733237" WEIGHT="16.056295500743662"/>
<DICH_DATA CI_END="1.6602616312734333" CI_START="0.7430000560779426" EFFECT_SIZE="1.1106639839034205" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="43" LOG_CI_END="0.22017653145277316" LOG_CI_START="-0.1290111534610396" LOG_EFFECT_SIZE="0.04558268899586677" MODIFIED="2008-01-11 22:37:32 -0500" MODIFIED_BY="[Empty name]" ORDER="60" O_E="0.0" SE="0.20511457462529092" STUDY_ID="STD-DeJonge-2007" TOTAL_1="994" TOTAL_2="989" VAR="0.04207198872371404" WEIGHT="83.94370449925634"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.7354381870440054" CI_START="0.37081270245571996" DF="0.0" EFFECT_SIZE="1.176923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" I2="0.0" ID="CMP-001.18.04" LOG_CI_END="0.5723415542245309" LOG_CI_START="-0.43084539720300696" LOG_EFFECT_SIZE="0.07074807851076205" MODIFIED="2008-01-17 10:29:16 -0500" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.7822052608564918" STUDIES="1" TAU2="0.0" TOTAL_1="104" TOTAL_2="102" WEIGHT="100.0" Z="0.2764463506212615">
<NAME>Serious adverse events (Altastaph vs. placebo)</NAME>
<DICH_DATA CI_END="3.7354381870440054" CI_START="0.37081270245571996" EFFECT_SIZE="1.176923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5723415542245309" LOG_CI_START="-0.43084539720300696" LOG_EFFECT_SIZE="0.07074807851076205" MODIFIED="2008-01-17 10:29:16 -0500" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.5892769811240336" STUDY_ID="STD-Benjamin-2006" TOTAL_1="104" TOTAL_2="102" VAR="0.3472473604826546" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>